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1.  Selected Publications Representing the “Kumulative Habilitationsschrift” 
 
 
The following six publications have been selected as a documentation of my research 
activities in the field of drug safety and pharmacoepidemiology: 
 
 
• Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 
2001;135(1):68-9. (Case report) 
Impact Factor (2005): 13.254 
 
• Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with 
flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from 
the UK General Practice Research Database. Br J Clin Pharmacol 2005;60(1):76-82. 
Impact Factor (2005): 2.777 
 
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of non-fatal venous thromboembolism 
comparing ORTHO EVRA™ with oral contraceptives containing norgestimate and 35 µg 
of ethinyl estradiol. Contraception 2006; 73(3);223-228. 
Impact Factor (2005): 1.713 
 
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of Nonfatal Venous Thromboembolism 
Comparing Oral Contraceptives Containing Norgestimate or Desogestrel with Oral 
Contraceptives Containing Levonorgestrel. Contraception 2006; 73(6):566-570. 
Impact Factor (2005): 1.713 
 
• Jick H, Kaye JA, Russmann S, Jick S. NSAIDs and acute myocardial infarction in 
patients with no major risk factors. Pharmacotherapy 2006; 26(10):1379-87. 
Impact Factor (2005): 1.920 
 
• Russmann S, Lamerato L, Marfatia A, Motsko SP, Pezzullo J, Olds G, Jones JK. Risk of 
Impaired Renal Function After Colonoscopy: A Cohort Study in Patients Receiving Either 
Oral Sodium Phosphate or Polyethylene Glycol. American Journal of Gastroenterology, 
2007 in press. 
Impact Factor (2005): 5.116 
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2.  Background and Presentation of a Conceptual Framework 
 
Spontaneous reports and “the birth of pharmacovigilance” 
Although new drugs have to undergo testing in pre-clinical and clinical (Phase I to III) trials, 
rare adverse drug reactions are often not identified before the post-marketing phase (Phase 
IV) in the form of spontaneous reports. Probably the most tragic historical example is the 
disaster of thalidomide-induced birth defects (1, 2), and the consequent efforts to 
systematically collect and evaluate reports of spontaneous adverse drug reactions 
constituted the birth of active drug safety surveillance, or “pharmacovigilance”. Until today, 
probably most acute severe adverse drug reactions are first made public and reach 
prescribing and regulatory health professionals through spontaneous reports by vigilant 
health care providers or patients. Such reports may subsequently be evaluated by trained 
health professionals based on categorized criteria of “intrinsic” evidence, i.e. temporal 
relationship, exclusion of other causes, improvement upon dechallenge and reoccurrence 
after rechallenge, as well as specific diagnostic evidence. In addition, “extrinsic” evidence, 
i.e. information from other comparable reports and mechanistic hypotheses based on 
pathophysiological and pharmacological considerations, is also taken into account. The 
combined evidence is then evaluated and weighted according to guidelines, resulting in a 
semi-quantitative case causality assessment ranging from “unlikely” over “possible and 
“probable” to “certain”. Eventually, these adverse drug reaction reports are collected in large 
databases such as the one maintained by the WHO Collaborating Centre for International 
Drug Monitoring, which are supposed to generate „signals“, i.e. identify and communicate 
previously unknown drug safety issues (3). 
The principle limitation of such spontaneous reporting systems is the fact that neither the true 
drug exposure (the “denominator”), nor the true incidence of adverse drug reactions (the 
“numerator”) within the monitored population are known, i.e. any attempts to quantify the 
occurrence of adverse drug reactions would have to be based on rather crude and generally 
unreliable assumptions (4). Further, unspecific reactions with a high „background rate“ or 
those with a long latency time are generally not suitable for detection through spontaneous 
reports. In spite of these intrinsic limitations, I support the view that spontaneous reports 
make a significant contribution to drug safety as long as their use and interpretation is limited 
to non-quantitative signal generation (5). 
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Randomized clinical trials for the evaluation of drug safety 
In contrast to spontaneous reporting systems, precise quantitative information is the principle 
strength of (controlled, randomized) clinical trials. Consequently there is little doubt that they 
constitute the gold standard for efficacy outcomes, and the mandatory systematic collection 
and analysis of all adverse events during clinical trials also contributes important safety 
information. However, also clinical trials have intrinsic limitations, and some of these are 
particularly relevant for drug safety: the detection of rare but serious adverse reactions would 
require the inclusion of several thousand or even ten-thousand patients; the setting of clinical 
trials is “artificial” and does therefore not reflect a drug’s safety profile in clinical practice, for 
instance certain subpopulations with a potentially higher risk for adverse reactions are 
excluded, drugs are taken in highly standardized dosage regimens and only during a short 
time; and furthermore long time periods for planning and conduct of clinical trials with high 
associated costs usually preclude the availability of required safety information for the right 
question at the right time (e.g. when a new safety issue is raised after marketing) in the 
relevant population. 
 
Pharmacoepidemiology and Drug Safety 
Epidemiological or “observational” studies are generally considered to be inferior to clinical 
trials as far as the level of evidence for efficacy outcomes is concerned. However, particularly 
in the area of drug safety they can overcome many of the mentioned intrinsic limitations of 
clinical trials: they can efficiently include a large number of patients considered to be 
representative of the population that uses a drug in clinical practice including patients at risk 
for adverse reactions; they reflect “real-life”-drug use and therefore also allow the study of 
drug utilization patterns; and they are generally easier, faster, more flexible and more 
economical to realize than clinical trials. 
The basic formal epidemiological study designs and essential principles, i.e. (comparison) 
cohort studies and case-control study designs that aim to isolate exposures and outcomes of 
interest in the best possible way are also applied in drug safety epidemiology. Also the 
principle tools to control for confounding, i.e. restriction, stratification with and without pooled 
estimates (6), and regression modeling, have been used for a long time. However, the 
availability of large high quality automated databases that include the electronic information 
of several million patients has increased exponentially during the past five to ten years. In 
addition, refined and easier to use statistical methods and software allow better control of 
residual confounding, e.g. through conditional logistic regression or propensity score-based 
regression modeling (7). These changes have indeed taken the contribution of 
pharmacoepidemiology for the efficient evaluation of drug safety to a new dimension. 
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3.  Discussion of the Selected Publications 
 
Kava hepatotoxicity 
Although this first selected publication is “just” a case report, it is a good example for the 
value and subsequent impact of a well-documented published spontaneous report when little 
other safety data is available (8). Almost simultaneously with two other groups (9, 10), we 
published the first cases of severe hepatotoxicity associated with phytotherapeutics 
containing Kava-lactones. Beyond the usual extensive differential diagnostic workup, we also 
performed a relatively specific lymphocyte transformation test, and the formal causality 
assessment was therefore able to link hepatotoxicity with a high probability to Kava exposure 
in this case. Subsequently we also followed this signal with two prospective studies (11, 12). 
Because Kava was sold as a non-prescription phytotherapeutic in most countries, it was less 
strictly regulated, and there was consequently relatively little safety information from 
preclinical and clinical trials available. Kava-induced hepatotoxicity is presumably very rare, 
and it is therefore also unlikely that this safety issue would have been detected in clinical 
trials.  And because Kava products were sold over the counter, they were also not 
documented in available patient databases precluding an epidemiological study. In the light 
of weak evidence for efficacy, the risk-benefit assessment of regulatory authorities was 
eventually driven by well-documented case-reports indicating a potentially lethal adverse 
reaction, and Kava was subsequently withdrawn from the markets in Australia, New Zealand, 
most European (including Switzerland, Germany and France) and other countries world-
wide. 
 
Flucloxacillin hepatotoxicity 
The second selected publication also concerns hepatotoxicity, being one of the most severe 
and therefore clinically relevant adverse drug reactions (13). Here however, we were able to 
conduct an epidemiological study and to estimate the absolute and relative incidence of 
hepatotoxicity associated with flucloxacillin in one of the world’s largest and best-validated 
databases, the UK General Practice Research Database. Several important principles of 
drug safety epidemiology are demonstrated in this study. First, we rigorously validated all 
potential cases through review of original clinical records, excluded patients with identifiable 
other causes of liver disease, and thus achieved the best possible specificity for the 
diagnosis of flucloxacillin-induced liver disease. Because unspecific case criteria tend to bias 
the relative risk estimate to the null in epidemiological studies, this in fact also increases the 
sensitivity to detect differences as compared to the comparison cohort. Second, the selection 
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of a suitable comparison cohort exposed to a drug with little or even no hepatotoxicity helps 
to correct the absolute incidence for any possible residual unspecific hepatotoxicity and may 
also allow clinically relevant comparisons with alternative treatments. Third, we used a time-
period incidence as opposed to an incidence rate and included only first-time drug 
exposures. This decision was based on a thorough study of all significant reports in the 
literature, leading to the hypothesis that the adverse reaction of interest strikes early in 
susceptible patients or not at all. 
 
Venous thromboembolism associated with a new hormonal contraceptive patch 
The next two publications represent good examples of the value of epidemiological safety 
studies for the fast and efficient evaluation of an urgent safety signal that was generated by 
spontaneous reports (14, 15). About a dozen reports of fatal venous thromboembolism in 
young women using a new contraceptive patch had raised major concern about its safety, 
and the US regulatory authority (FDA) urgently required additional safety data from the 
manufacturer. Attempts to derive quantitative risk estimates from spontaneous reports and 
marketing data were uninterpretable due to unknown adverse event reporting rates, and 
imprecise drug exposure information in the population at risk. In addition, venous 
thromboembolism is not a specific drug-attributable event (relatively high “background risk”), 
but may have other known or unknown causes, i.e. individual case causality evaluation can 
at the most conclude on a possible causal relationship with the drug exposure of interest. 
Further, a clinical trial could not be conducted under the given time pressure for a regulatory 
decision, and would have been unable to include a sufficient number of patients to quantify a 
rare drug effect anyway. The incidence under the drug of interest therefore had to be 
compared to the incidence during exposure to a suitable comparison drug in a comparable 
population in a readily available data souce. 
We were able to conduct such a study in a large US insurance claims database, plus an 
additional study that put the comparison drug of our first study into the perspective of the 
ongoing discussion of the risk of venous thromboembolism in users of second vs. third 
generation oral contraceptives. In these two studies we found evidence for an increased risk 
of venous thromboembolism associated with use of the new contraceptive patch vs. no use, 
but not vs. an established oral contraceptive, and the contraceptive patch has consequently 
not been withdrawn. 
 
Selective COX2-inhibitors and myocardial infarction 
This study addresses an issue that has received considerable attention after the 
cyclooxygenase-2 selective (COX2) nonsteroidal anti-inflammatory drug (NSAID) rofecoxib 
(Vioxx®) had been associated with an increased risk of cardiovascular events and 
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subsequently been withdrawn from the market (16). Although this finding was first observed 
in a large randomized clinical trial, the results of this trial left many questions unanswered, 
such as an extended comparison with other NSAIDs and other populations. We therefore 
conducted a database study on this issue, and in order to achieve the best possible control 
of confounding, we used a nested case-control design where we excluded all patients with 
other identifiable causes and risk factors for myocardial infarction (restriction as a tool to 
control for confounding), matched cases and controls on age, gender, time and practice, and 
subsequently performed a conditional logistic regression analysis considering additional 
covariables including cumulative drug exposure (17). Our findings indicated that those 
NSAIDs with a high selectivity for COX2 (rofecoxib, celecoxib and diclofenac) were 
associated with a higher risk of myocardial infarction, whereas ibuprofen and naproxen were 
not. 
 
Renal function after colonoscopy using different bowel cleansing preparations  
The last study concerns a safety issue that was triggered by spontaneous reports of severe 
renal dysfunction after use of oral bowel cleansing agents containing sodium phosphate (18). 
For this study we were able to link the large database of the Henry Ford Health System, with 
the local database of affiliated gastroenterology clinics in Detroit, and subsequently 
conducted a cohort study comparing users of sodium phosphate vs. poylethylenglycol for 
bowel preparation before colonoscopy. In this study we first used restriction as a powerful 
and robust method to control for confounding related to a possibly preferred use of 
polyethylenglycol in patients with preexisting renal dysfunction: we a priori excluded patients 
with severe preexisting renal dysfunction from the study population. Although we needed to 
exclude a substantial proportion of patients, we believe that this step was necessary in order 
to obtain robust and interpretable results that are not heavily based on assumptions of 
regression models. For the further analysis we then applied a propensity score-based 
regression model, which is a relatively new method that conceptually attempts to mimic the 
randomization process in a clinical trial, and is supposed to be more robust when several 
covariables but only a limited number of outcomes have to be analyzed (7). 
 
 
4.  Future Perspectives 
 
The presented research and related background and discussion aimed to provide examples 
and a conceptional framework for the application of pharmacoepidemiological methods in the 
evaluation of drug safety. I would like to emphasize that I do not consider 
pharmacoepidemiology as an alternative, but as a necessary complementary approach, and 
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would indeed define four principle sources for information in the evaluation of drug safety i.e. 
1) pre-clinical in-vitro and animal studies, 2) clinical trials, 3) spontaneous reports, and 4) 
formal epidemiological drug safety studies, such as the ones that have been presented and 
discussed. The integration of information from all of these four principle sources and 
approaches is essential for a comprehensive evaluation of a drug’s safety profile in a 
relevant context. 
Today, pharmacoepidemiology makes a substantial contribution to the evaluation of drug 
safety, and given an increasing number and size of suitable databases on the one hand, and 
new regulatory requirements and recommendations on the other hand, this contribution will 
likely further increase its impact on drug safety for clinicians, pharmaceutical industrial or 
regulatory authorities in the near future (19). In particular, pharmacoepidemiology is 
increasingly used as a suitable method for a more proactive safety management during the 
early post-marketing phase of new drugs. 
Although the presented studies mainly focused on the use of pharmacoepidemiology for the 
quantification of absolute and relative risks and the identification of risk factors, one may 
argue that for drugs that continue to be marketed the “safety mission is not completed” until 
the gained knowledge is actually transferred back to the studied populations at risk through 
the implementation of preventive measures in clinical practice. In this context I finally want to 
mention that the same electronic patient data systems that are used for the conduct of 
pharmacoepidemiological studies, may also be used for the subsequent development and 
local implementation of preventive measures (20). Indeed, at the University Hospital Zurich 
we currently plan to use electronic drug prescriptions and comprehensive patient information, 
not only for the local identification of drug safety issues, but also for the establishment of so-
called electronic clinical decision support systems, which have been shown to be effective for 
the improvement of outcomes and reduction of costs in hospitalized patients. 
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Selected Publications Representing the “Kumulative Habilitationsschrift” 
 
 
The following six publications have been selected as a documentation of my research 
activities in the field of drug safety and pharmacoepidemiology: 
 
 
• Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 
2001;135(1):68-9. (Case report) 
Impact Factor (2005): 13.254 
 
• Russmann S, Kaye JA, Jick SS, Jick H. Risk of cholestatic liver disease associated with 
flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from 
the UK General Practice Research Database. Br J Clin Pharmacol 2005;60(1):76-82. 
Impact Factor (2005): 2.777 
 
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of non-fatal venous thromboembolism 
comparing ORTHO EVRA™ with oral contraceptives containing norgestimate and 35 µg 
of ethinyl estradiol. Contraception 2006; 73(3);223-228. 
Impact Factor (2005): 1.713 
 
• Jick SS, Kaye JA, Russmann S, Jick H. Risk of Nonfatal Venous Thromboembolism 
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Contraceptives Containing Levonorgestrel. Contraception 2006; 73(6):566-570. 
Impact Factor (2005): 1.713 
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patients with no major risk factors. Pharmacotherapy 2006; 26(10):1379-87. 
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• Russmann S, Lamerato L, Marfatia A, Motsko SP, Pezzullo J, Olds G, Jones JK. Risk of 
Impaired Renal Function After Colonoscopy: A Cohort Study in Patients Receiving Either 
Oral Sodium Phosphate or Polyethylene Glycol. American Journal of Gastroenterology, 
2007 in press. 
Impact Factor (2005): 5.116 
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Background and Presentation of a Conceptual Framework 
Three principle methods are available for the evaluation of a drug’s clinical safety profile, i.e. 
spontaneous reports, clinical trials, and formal pharmacoepidemiological studies. 
 
Spontaneous reports 
Most acute severe adverse drug reactions are first made public and reach prescribing and 
regulatory health professionals through spontaneous reports by vigilant health care providers 
or patients. For a standardized assessment, the combined evidence from individual reports is 
evaluated and weighted according to guidelines, resulting in a semi-quantitative case 
causality assessment. Reports are subsequently collected in large databases, which are 
supposed to generate „signals“, i.e. identify previously unknown drug safety issues. The 
principle limitation of such spontaneous reporting systems is the fact that neither the true 
drug exposure, nor the true incidence of adverse drug reactions are known, i.e. any attempts 
to quantify the occurrence of adverse drug reactions will provide a rather crude and generally 
unreliable approximation. Further, unspecific reactions with a high „background rate“ or those 
with a long latency time are generally not suitable for detection through spontaneous reports. 
 
Randomized clinical trials for the evaluation of drug safety 
In contrast to spontaneous reporting systems, precise quantitative information is the principle 
strength of clinical trials. They consequently constitute the gold standard for efficacy 
outcomes, and the mandatory systematic collection and analysis of all adverse events during 
clinical trials also contributes important safety information. However, also clinical trials have 
intrinsic limitations, and some of these are particularly relevant for drug safety: the detection 
of rare but serious adverse reactions would require the inclusion of several thousand or even 
ten-thousand patients; the setting of clinical trials is “artificial” and does therefore not reflect a 
drug’s safety profile in clinical practice; and furthermore long time periods for planning and 
conduct of clinical trials with high associated costs usually preclude the availability of 
required safety information for the right question at the right time in the population of interest. 
 
Pharmacoepidemiology and Drug Safety 
Epidemiological or “observational” studies are generally considered to be inferior to clinical 
trials as far as the level of evidence for efficacy outcomes is concerned. However, particularly 
in the area of drug safety they can overcome many of the mentioned intrinsic limitations of 
clinical trials: they can efficiently include a large number of patients considered to be 
representative of the population that uses a drug in clinical practice; they reflect “real-life”-
drug use and therefore also allow the study of drug utilization patterns; and they are 
generally easier, faster, more flexible and more economical to realize than clinical trials. In 
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recent years, the availability of large high quality automated databases that include the 
electronic information of several million patients has increased exponentially. In addition, 
refined and easier to use statistical methods allow better control of residual confounding, and 
also current regulatory guidelines now demand a proactive post-marketing safety 
management using pharmacoepidemiological methods. 
 
Discussion of the Selected Publications 
Kava hepatotoxicity 
In this publication we describe one of the first cases of severe hepatotoxicity associated with 
phytotherapeutics containing Kava-lactones. Although “just” a case report, it is a good 
example for the value and subsequent impact of a well-documented published spontaneous 
report when little other safety data is available. In the light of weak evidence for efficacy, the 
risk-benefit assessment of regulatory authorities was eventually driven by well-documented 
case-reports indicating a potentially lethal adverse reaction, and Kava was subsequently 
withdrawn from the markets in many countries world-wide including Switzerland. 
 
Flucloxacillin hepatotoxicity 
The second presented work also concerns hepatotoxicity, but in this case we were able to 
conduct an epidemiological study and to estimate the absolute and relative incidence of 
hepatotoxicity associated with flucloxacillin in one of the world’s largest and best-validated 
databases, the UK General Practice Research Database. Several important principles of 
drug safety epidemiology are demonstrated in this study: the importance of thorough case 
review and validation, the necessary exclusion of patients with identifiable other causes of 
the outcome of interest, criteria for the selection of a suitable comparison cohort, and the role 
of “susceptible” time in the study case definition. 
 
Venous thromboembolism associated with a new hormonal contraceptive patch 
The next two publications represent good examples of the value of epidemiological safety 
studies, when a fast and efficient evaluation of an urgent safety signal is required. About a 
dozen reports of fatal venous thromboembolism in young women using a new contraceptive 
patch had raised major concern about its safety, and attempts to derive quantitative risk 
estimates from spontaneous reports and marketing data, or from clinical trials data was too 
unreliable due to the above mentioned intrinsic limitations of these approaches. In this 
situation we were able to conduct two epidemiological safety studies in a large US insurance 
claims database. We found evidence for an increased risk of venous thromboembolism 
associated with use of the new contraceptive patch vs. no use, but not vs. an established 
oral contraceptive. 
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Selective COX2-inhibitors and myocardial infarction 
This study addresses an issue that has received considerable attention after the 
cyclooxygenase-2 selective (COX2) nonsteroidal anti-inflammatory drug (NSAID) rofecoxib 
(Vioxx®) had been associated with an increased risk of cardiovascular events and 
subsequently been withdrawn from the market. We addressed several issues that had been 
left unanswered and used a study design and data analysis that aimed for the best possible 
control of confounding. Our findings indicated that those NSAIDs with a high selectivity for 
COX2 were associated with a higher risk of myocardial infarction, whereas others were not, a 
result that is compatible with pathophysiological considerations as well as with other studies. 
 
Renal function after colonoscopy using different bowel cleansing preparations  
The last study concerns a safety issue that was triggered by spontaneous reports of severe 
renal dysfunction after use of oral bowel cleansing agents containing sodium phosphate. In 
this study we first used restriction as a powerful and robust method to control for 
confounding, and then applied a propensity score-based regression model, which is a 
relatively new method that conceptually attempts to mimic the randomization process in a 
clinical trial, and is supposed to be more robust when several covariables but only a limited 
number of outcomes have to be analyzed. Our results suggest that at least in patients with 
normal kidneys there is no increased risk of renal dysfunction after use of sodium phosphate 
compared to polyethylenglycol. 
 
Future Perspectives 
Today, pharmacoepidemiology makes a substantial contribution to the evaluation of drug 
safety, and given an increasing number and size of suitable databases on the one hand, and 
new regulatory requirements and recommendations on the other hand, this contribution will 
likely further increase its impact on drug safety for clinicians, pharmaceutical industry and 
regulatory authorities in the near future. In addition, the same electronic patient data systems 
that are used for the conduct of pharmacoepidemiological studies, may also be used for the 
subsequent development and local implementation of preventive measures. Indeed, at the 
University Hospital Zurich we currently plan to use electronic drug prescriptions and 
comprehensive patient information not only for the local identification of drug safety issues, 
but also for the establishment of so-called electronic clinical decision support systems, which 
have been shown to be effective for the improvement of outcomes and reduction of costs in 
hospitalized patients. 
 
4. Lickint F. Tabak und Organismus; Handbuch der gesamten Tabakkunde. Stuttgart:
Hippokrates; 1939.
5. Summary of the Report of the Surgeon General’s Advisory Committee on Smoking
and Health. U.S. Surgeon General’s Advisory Committee on Smoking and Health.
Washington, DC: U.S. Department of Health, Education, and Welfare; 1964.
IN RESPONSE: We appreciate the interest in our recent article on
smoking and renal abnormalities in nondiabetic persons. As Drs.
Mehler and Estacio point out, smoking has been found to have
adverse effects on renal function not only in patients with type 1
diabetes mellitus but also in those with type 2 diabetes mellitus (1).
We agree with their plea that physicians should strongly encourage
cessation of smoking in patients with type 2 diabetes mellitus. Our
finding that smoking is also associated with both albuminuria and
renal function changes in patients without diabetes argues that smok-
ing has renal effects independent of the diabetic setting. It adds to
our knowledge about the mechanism of albuminuria. Increased uri-
nary albumin excretion seems to be a phenomenon related not only
to diabetes and hypertension but also to smoking, central obesity
(Pinto-Sietsma SJ, Navis G, Janssen WM, de Zeeuw D, Gans RO,
de Jong PE. A central body fat distribution is related to renal abnor-
malities. Unpublished data), and the use of oral contraceptives and
hormone replacement therapy (2). This may partly explain why mi-
croalbuminuria may also be found in 5% to 6% of nondiabetic and
nonhypertensive persons.
We thank Dr. Jay for drawing attention to the medical litera-
ture as early as 1922. At that time, it indeed was already reported
that smoking could cause Bright disease, known in those days as
congestion, degeneration, and damage of the kidney. Furthermore, it
was described that tobacco induced a pronounced contraction of the
vessels of the kidney (3). These and other historical data, as pointed
out by Dr. Jay, underline the importance and difficulties of the
struggle for smoking cessation. Microalbuminuria is thought to be an
early marker for worsened renal and cardiovascular prognosis. There-
fore, our finding that patients who stopped smoking no longer had
an increased risk for microalbuminuria argues for a more aggressive
and intensive approach to encourage smoking cessation in patients
with microalbuminuria, both those with diabetes and those without.
Sara-Joan Pinto-Sietsma, MD
Wilbert M.T. Janssen, MD, PhD
Paul E. de Jong, MD, PhD
University Hospital Groningen
9713 GZ Groningen, the Netherlands
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Kava Hepatotoxicity
TO THE EDITOR: Phytotherapeutic preparations for sleep and anxi-
ety disorders that contain kava-lactones are available over the counter
in many countries. A 33-year-old woman took the drug Laitan
(Schwabe Pharma AG, Kuessnacht, Switzerland) (210 mg of kava-
lactones daily) for 3 weeks. The patient reported intake of no other
drugs except the homeopathic medication Exsepta (Tentan AG, Roth-
rist, Switzerland). Two months later, she restarted use of the kava
preparation. After another 3 weeks, 1 day after intake of 60 g of
alcohol, she developed malaise, loss of appetite, and jaundice. Levels
of aminotransferases, bilirubin, and alkaline phosphatase were ele-
vated 60-, 15- and 3-fold, respectively (aspartate aminotransferase,
40.8 !kat/L [2450 U/L]; alanine aminotransferase, 40.5 nkat/L
[2430 U/L]; total bilirubin, 399 !mol/L [23 mg/dL]; alkaline phos-
phatase, 4.98 !kat/L [299 U/L]). Prothrombin time was normal.
Tests for autoantibodies and results of viral serologic tests were neg-
ative, except for low titers of Epstein–Barr virus IgM. Liver biopsy
showed infiltrated portal tracts, bridging necroses, destruction of in-
terlobular bile ducts, and canalicular cholestasis (Figure). Liver en-
zyme levels returned to normal within 8 weeks after withdrawal of
Laitan. A lymphocyte transformation test (1) performed after recov-
ery indicated strong and concentration-dependent T-cell reactivity to
Laitan (stimulation index, 13.2) but not Exsepta. Phenotyping of
cytochrome P4502D6 activity with debrisoquine showed that the
patient was a poor metabolizer. We also performed phenotyping in a
patient who had had positive results on a rechallenge test (3) and
found that she was a poor metabolizer of debrisoquine. Since the
local prevalence of CYP2D6 deficiency is 9% (4), the probability
that two consecutive patients are deficient is less than 0.01%.
Figure. Liver biopsy specimen showing an inflamed
portal tract.
A mixed cellular infiltrate is dominated by lymphocytes, exhibits eosin-
ophil granulocytes and activated macrophages, and involves an interlob-
ular bile duct (hematoxylin–eosin stain; original magnification, ! 175).
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The histologic findings and the results of the lymphocyte trans-
formation test are compatible with an immune-mediated reaction,
possibly mediated through a reactive metabolite. In humans, kava-
lactones are metabolized through hydroxylation (2), but the involved
enzymes have not been identified. The present data strongly suggest
that kava preparations may be hepatotoxic and that CYP2D6 defi-
ciency is a risk factor, as is the antianginal agent perhexiline (5).
Stefan Russmann, MD
Bernhard H. Lauterburg, MD
University of Bern
3010 Bern, Switzerland
Arthur Helbling, MD
Inselspital
3010 Bern, Switzerland
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Medication Assistance Programs
TO THE EDITOR: Prescription medications are the most rapidly ex-
panding component of national health care expenses. Ninety billion
dollars were spent on prescription drugs in 1998, and this number is
projected to increase to $171 billion by 2007, representing 8% of
total national health care expenditures (1). Approximately 16% of
the U.S. population does not have health insurance, and a greater
percentage has health insurance that does not include a prescription
medication benefit (2). Therefore, it is becoming increasingly diffi-
cult for some segments of the population to purchase the prescrip-
tion drugs that they need.
Many pharmaceutical companies offer assistance by providing
free or reduced-cost medications to patients who meet specific finan-
cial criteria. A wide range of medications for many indications are
provided in these programs. Drugs may be provided free, or patients
may be required to pay a fee or shipment charge. Medications are
supplied by direct delivery to the patient or physician, or the patient
may be issued a benefit card or voucher that must be presented at a
pharmacy. The amount of medications given and the length of time
that a patient may be enrolled vary.
Physician involvement is necessary for patient enrollment in
these programs, so clinicians must be informed about them to in-
crease patient access to medications. Information concerning medi-
cation assistance programs sponsored by pharmaceutical companies
can be obtained from a variety of sources, including Pharmaceutical
Research and Manufacturers of America, such publications as Reim-
bursement Assistance Programs Sponsored by the Pharmaceutical Indus-
try and the Directory of Prescription Drug Patient Assistance Programs,
and various Internet sites (3, 4). However, the best source of infor-
mation about assistance programs and specific details concerning
patient eligibility and program enrollment is the manufacturer of the
medication.
Of course, these programs are not the solution to this universal
problem of medication access, and it is important to note that they
operate at the discretion of the pharmaceutical company and may there-
fore be terminated at any time. Nonetheless, it is equally important
to be aware of their existence as a possible source for medications.
The Appendix Table, available on the Annals Web site (www.annals
.org), provides an extensive listing of many medications whose man-
ufacturers offer medication assistance programs (5).
Marie A. Chisholm, PharmD
Joseph T. DiPiro, PharmD
University of Georgia College of Pharmacy
Athens, GA 31062
Medical College of Georgia
Augusta, GA 30912-2450
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Acute Renal Failure Related to High-Dose Celecoxib
TO THE EDITOR: A 57-year-old woman developed acute renal failure
on 6 July 2000. She had been prescribed celecoxib, 200 mg/d, 10
months earlier for symptomatic osteoarthritis and had been followed
with bimonthly visits thereafter. Her baseline creatinine and blood
urea nitrogen (BUN) levels were normal at 88 !mol/L (1.0 mg/dL)
and 3.9 mmol/L (11 mg/dL), respectively. In the last half of June
2000, her orthopedist doubled the daily celecoxib dose to 400 mg.
Two weeks later, on 6 July 2000, she presented with marked depen-
dent edema and markedly elevated blood pressure (160/110 mm
Hg). Creatinine and BUN levels were elevated at 265 !mol/L (3.0
mg/dL) and 15.4 mmol/L (43 mg/dL), respectively. Celecoxib ther-
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Aims
 
To provide additional quantification of the risk of flucloxacillin-related liver disease
and to describe time trends in flucloxacillin prescribing in the UK.
 
Methods
 
This was a cohort study using data from the UK General Practice Research Database.
We identified patients with a first-time prescription for flucloxacillin or, for comparison,
oxytetracycline from 1992 to 2002 and cases who developed clinically documented
cholestatic liver disease of uncertain origin after first-time use of these drugs. We also
determined the annual frequency of first-time use of flucloxacillin from 1991 to 2000.
 
Results
 
We identified 283 097 and 131 189 first-time users of flucloxacillin and oxytetracy-
cline, respectively. The risk of cholestatic liver disease per 100 000 first-time users
was 8.5 (95% CI 5.4, 12.6) in the 1–45 days and 1.8 (95% CI 0.6, 4.1) in the 46–
90 days after starting flucloxacillin, and 0.8 (95% CI 0.02, 4.3) in the 1–45 days
after starting oxytetracycline. The frequency of first-time use of flucloxacillin remained
stable between 1991 and 2000.
 
Conclusions
 
Flucloxacillin is now established as an important cause of cholestatic liver disease.
Warnings about the risk have not had an impact on prescribing practices in the UK,
where it remains the predominantly prescribed antistaphylococcal oral antibiotic. This
situation in the UK is in sharp contrast to regulatory actions and changes in prescribing
habits in Australia after identification of the risk of cholestasis associated with fluclox-
acillin, and to the predominant use of the alternative drug dicloxacillin in the USA.
 
Introduction
 
Flucloxacillin is a penicillinase-resistant halogenated
semisynthetic isoxazolyl penicillin used for the oral
antibiotic treatment of soft tissue infections caused by
 
Staphylococcus aureus
 
 (
 
S. aureus
 
). Initial case reports
from the Netherlands and Scandinavia in the 1980s
reported cholestatic liver disease of unknown origin
occurring in flucloxacillin users, and subsequently
numerous similar reports including several case series
from Australia [1–13]. From these reports a well-defined
clinical picture of flucloxacillin-associated liver disease
was described, which consisted of prolonged painless
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jaundice with elevation of cholestatic liver enzymes
diagnosed within 2–6 weeks after prescription, and as
much as 3 weeks after the drug was stopped. Although
most patients eventually recovered within several
months, a chronic vanishing bile duct syndrome was
reported in some patients [5, 9, 10, 14], and fatal cases
were also described [5, 7]. In the early 1990s two pop-
ulation-based epidemiological studies were performed
with data from the UK General Practice Research Data-
base (GPRD), which estimated the risk of cholestatic
liver disease within 45 days after first-time use of flu-
cloxacillin at about 7 in 100 000 patients [15, 16].
By 1994 the Australian Adverse Drug Reactions
Advisory Committee had received 310 reports of liver
disease in association with the use of flucloxacillin,
including 17 cases with a fatal outcome [17]. After 1994
the Australian Department of Human Services and
Health restricted the use of flucloxacillin to severe infec-
tions, all advertising by the manufacturer was stopped,
and cephalexin and erythromycin were recommended
and advertised as alternative treatments [18]. Subse-
quently prescription dispensings in Australia decreased
by about 30% between June 1994 and December 1995
[18]. In the UK only a warning was published by the
Medicines Controls Agency (MCA) in the Current Prob-
lems in Pharmacovigilance bulletin in 1992 [19], and
flucloxacillin is still recommended as first-line treatment
for soft-tissue infections caused by 
 
S. aureus
 
 [20].
The primary objective of the current study was to
update the frequency estimation of cholestatic liver dis-
ease associated with the use of flucloxacillin within the
population of the GPRD from 1992 to 2002. Given that
in Australia a major change in the usage pattern of
flucloxacillin occurred, the second objective of this
study was to investigate the prescribing practices of
flucloxacillin in the UK following the MCA warning
letter and publications in medical journals regarding the
risk of flucloxacillin-induced cholestatic liver disease.
 
Methods
 
Data resource
 
The General Practice Research Database (GPRD) is a
population-based patient database that comprehensively
records medical diagnoses, hospital referrals, prescrip-
tions and demographic details from UK general prac-
tices. The GPRD has been described in detail and has
been used extensively for pharmacoepidemiological
studies. The data have been validated for completeness
and quality by the Boston Collaborative Drug Surveil-
lance Program and others [21]. Data collection for the
GPRD has also been described in detail in the previous
report on cholestatic liver disease associated with flu-
cloxacillin [16]. All the information we received was
identified by an anonymous patient number only.
 
Study population
 
From the GPRD we derived a study population of all
subjects with a first-time prescription of flucloxacillin
or oxytetracycline, recorded after 31 October 1992 (end
date of previous study [15]) to the end of data collection
in 2002.
 
Case definition
 
To detect cases of cholestatic liver disease of uncertain
origin, we used similar criteria as in the previous studies
[15, 16]. All subjects with a coded diagnosis related to
cholestatic liver disease recorded within 1–45 days after
a prescription for flucloxacillin were identified from the
study population. The restriction to cholestatic forms of
liver disease and to the interval of 1–45 days after pre-
scription were chosen because of the characteristic clin-
ical picture of flucloxacillin-associated liver disease
described in clinical reports of liver disease associated
with flucloxacillin [1–13]. For comparison we identified
all subjects with a coded diagnosis related to cholestatic
liver disease 1–45 days after a prescription for oxytetra-
cycline, a drug that has not been associated with chole-
static liver disease. In addition we also looked for cases
of cholestatic liver disease with an onset between 46 and
90 days after prescription of flucloxacillin in the cohort
of flucloxacillin users. The comparison with the risk of
cholestatic liver disease in oxytetracycline users and
during the period of 46–90 days in flucloxacillin users
was chosen in order to control for potential selection
bias that may be related to the prescription of antibiotic
treatment or other unknown factors. The computer-
recorded information on all those subjects was then indi-
vidually reviewed by two of the authors (SR and HJ).
For those cases where computer-recorded data were
consistent with the diagnosis of idiopathic cholestatic
liver disease, detailed clinical records were requested
from the corresponding practices, including relevant
consultant letters, laboratory test results and hospitaliza-
tion summaries. Subsequently cases were classified as
characteristic of drug-induced cholestatic liver disease
when they showed the typical clinical and laboratory
features of drug-induced cholestatic liver disease, i.e.
painless jaundice with predominant elevation of alkaline
phosphatase and bilirubin concentrations, and when no
other causes of cholestasis were identifiable. In cases
where we did not receive requested patient records
because patients had transferred out of the practice, we
based our assessment on the available computer-
recorded information, which often included laboratory
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liver function tests. We excluded all subjects where a
causal relationship was unlikely, i.e. if the history and/
or laboratory findings were not suggestive of cholestatic
liver disease, if a cause of liver disease other than the
drug under study was likely, or if the onset of liver
disease had occurred before exposure to the drug under
study.
 
Prescribing practices over time
 
The number of first-time flucloxacillin users and the
number of all subjects in the GPRD was recorded for
each year between 1991 and 2000, and the frequency of
first-time flucloxacillin users per 1000 subjects in the
GPRD was calculated.
 
Data analysis
 
We calculated the 45 day risks of cholestatic liver dis-
ease and their 95% confidence intervals for the time
periods of 1–45 days and 46–90 days after the first
recorded exposure to flucloxacillin, and 1–45 days after
the first recorded exposure to oxytetracycline. For the
categorical covariates of male or female sex, and age
below 60 years or higher, risk ratios and their 95% con-
fidence intervals were calculated. All calculations were
done with STATA statistical software, version 8.2 for
MacOS X (STATA corporation, College Station, Texas,
USA).
 
Results
 
We identified 283 097 patients with a first-time prescrip-
tion for flucloxacillin and 131 189 patients with a first-
time prescription for oxytetracycline from 1 November
1992 until end of data collection in 2002. Age and sex
distributions of these two populations are shown in
Table 1. After initial review of the computerized patient
records, clinical records were requested for 36 subjects,
of which 23 were received. After reviewing all available
additional clinical information we identified 30 cases
considered to be idiopathic cholestatic liver disease. Of
these cases, 24 occurred in the 1–45 days after starting
flucloxacillin, five occurred in the 46–90 days thereafter,
and one occurred in the 1–45 days after starting oxytet-
racycline. The diagnostic GPRD codes and individual
features of all included cases are presented in Tables 2
and 3, respectively. Six out of the 24 cases occurring 1–
45 days after flucloxacillin were hospitalized. In all but
two cases flucloxacillin was prescribed for soft tissue
infections. The median total dose and duration of treat-
ment in the identified cases of flucloxacillin-induced
cholestatic liver disease 1–45 days after exposure were
8 g (range 5–56 g) and 7 days (range 5–28 days),
respectively, and the median latency time between start
of flucloxacillin treatment and diagnosis of liver disease
was 25.5 days (range 14–44 days). The concomitant use
of a potentially hepatotoxic drug was observed in 4 out
of the 24 cases that occurred 1–45 days post flucloxacil-
lin, and in one out of the five cases that occurred 46–
90 days after flucloxacillin. In one case augmentin, in
 
Table 1a
 
Distribution of flucloxacillin users by age and sex
 
Age (years) Male Female Total row %
 
<
 
20 30599 28973 59572 21.0
20–39 38213 46603 84816 30.0
40–59 32966 36466 69432 24.5
60–79 22696 27267 49963 17.6
 
>
 
79 5814 13500 19314 6.8
Total column 130288 152809 283097
% 46.0 54.0
 
Table 1b
 
Distribution of oxytetracycline users by age and sex
 
Age (years) Male Female Total row %
 
<
 
20 10414 7546 17960 13.7
20–39 19780 23279 43059 32.8
40–59 16449 21170 37619 28.7
60–79 12281 14696 26977 20.6
 
>
 
79 2015 3559 5574 4.2
Total column 60939 70250 131189
% 46.5 53.5
 
Table 2
 
GPRD diagnostic codes of included cases
 
GPRD code Diagnosis
 
Oxmis codes
 
7852 Jaundice
576 A Obstructive jaundice
7852 JC Cholestatic jaundice
 
Read codes
 
J66y600 Obstructive jaundice nos
1675.11 Jaundice – symptom
J633.00 Hepatitis unspecified
R024.00 Jaundice (not of newborn)
R024111 Jaundice
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three cases erythromycin, and in one case trimethoprim-
sulfamethoxazole were prescribed in close temporal
relationship to flucloxacillin (Table 3), and they can
therefore not be ruled out as alternative causes for
cholestasis in these patients.
The estimated 45-day risk per 100 000 first-time users
1–45 days after flucloxacliin (8.48, 95% CI 5.43, 12.61)
was substantially higher than the risk 46–90 days after
flucloxacillin (1.77, 95% CI 0.57, 4.12) and 1–45 days
after oxytetracycline (0.76, 95% CI 0.02, 4.25)
(Table 4).
Only 25% of all first-time flucloxacillin users were
age 60 years or more, whereas 67% of patients with
cholestatic liver disease after flucloxacillin exposure
were within this age group. Subjects with an age of
60 years or above were 6.1 times more likely to develop
cholestatic liver disease after flucloxacillin exposure
than those with an age below 60 years (95% CI 2.9,
13.0). Sixteen out of the 24 cases were female (67%)
compared with 54% in the study population (relative
risk 1.7, 95% CI 0.7, 3.9).
The number of first-time flucloxacillin users between
1991 and 2000 remained stable at about 23 first-time
users per 1000 subjects in the GPRD per year (Figure
1), and also the average number of prescriptions per user
per year remained stable with a mean value of 1.23
(range of mean values for each year from 1991 to 2000
1.20–1.27).
 
Discussion
 
In the absence of a validated specific diagnostic test, the
establishment of the causal relationship of an adverse
event and a drug is a diagnosis of exclusion that is
particularly difficult if the manifestation occurs after
stopping the treatment and the recovery is prolonged, as
is typical for flucloxacillin-induced cholestasis [5, 7, 10,
 
Table 3
 
Individual features of all included cases
 
Age
(years) Sex
Latency
time (days)
Treatment
duration (days)
Total dose
(g) Indication Concomitant medication and comments
a) Cases 1–45 days after first exposure to flucloxacillin
 
Cases where detailed clinical records were available
 
1 69 F 41 10 10 Phlebitis History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
2 61 F 24 7 7 Eczema History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
3 58 F 33 7 7 Sebaceous
cyst
History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
4 69 M 25 7 28 Unknown Diagnostic work-up identified no other 
cause of liver disease.
5 61 M 42 14 28 Skin infection History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
6 35 F 25 7 14 Vaginal
infection
History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
7 87 F 26 7 7 Cellulitis Missed diagnosis caused extensive invasive
and noninvasive work-up.
8 68 F 33 14 14 Postop. wound
infection
History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
9 69 M 14 7 14 ‘Rash’ Augmentin 2 days after flucloxacillin
10 47 F 29 7 7 Cellulitis/
abscess
Erythromycin 7 days after flucloxacillin.
11 78 M 18 14 28 Cellulitis/
abscess
Diagnostic work-up identified no other
cause of liver disease.
12 42 F 22 5 5 Rosacea Diagnostic work-up identified no other 
cause of liver disease.
13 76 F 19 14 56 Postop. wound 
infection
History includes explicit expert diagnosis of
flucloxacillin-induced liver disease.
14 62 F 32 28 28 Phlebitis History includes explicit expert diagnosis of 
drug-induced liver disease. Erythromycin 
12 days before flucloxacillin
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Cases where only computer-recorded data were available
 
15 43 F 30 7 14 Postop. wound 
infection
16 83 F 21 5 5 Toe infection
17 61 F 24 7 14 Leg abscess
18 46 M 17 12 12 Finger wound 
infection
19 15 M 21 4 8 Hand wound 
infection
20 16 F 16 7 7 Chest infection Trimethoprim/sulfamethoxazole 8 days before
flucloxacillin
21 73 M 34 7 14 Pneumonia
22 68 F 37 7 7 Phlebitis
23 88 F 44 7 7 Cellulitis
24 85 M 36 6 6 Skin infection
 
b) Cases 46–90 days after first exposure to flucloxacillin
 
Cases where detailed clinical records were available
 
1 81 F 82 7 7 Cellulitis Three prescriptions within 6 weeks. Latency 
time, dose and treatment duration refer only 
to first prescription. History includes explicit 
expert diagnosis of drug-induced liver disease.
 
Cases where only computer-recorded data were available.
 
2 84 F 49 5 10 Cellulitis/
abscess
3 88 F 75 6 6 Abscess
4 49 F 63 5 5 ‘’lump
superficial
Erythromycin 15 days after flucloxacillin.
5 54 F 58 27 27 Phlebitis First flucloxacillin for 7 days, then flucloxacillin
plus ampicillin for 20 days. Latency time 
refers to first prescription.
 
c) Case 1–45 days after oxtetracycline
 
Detailed clinical records were available
 
1 47 M 26 5 5 Cough Computer-recorded data and detailed patient
records were available
 
.
 
Age
(years) Sex
Latency
time (days)
Treatment
duration (days)
Total dose
(g) Indication Concomitant medication and comments
 
Table 4
 
45 day risk estimates for cholestatic liver disease after first exposure to flucloxacillin or oxytetracycline
 
1–45 days post flucloxacillin 46–90 days post flucloxacillin 1–45 days post oxytetracycline
 
Study population 283 097 283 097 131 189
Cases 24 5 1
45 day risk with 8.48 (5.43, 12.61) 1.77 (0.57, 4.12) 0.76 (0.02, 4.25)
95% CI per 100 000 users
 
Table 3
 
Continued
 Cholestatic liver injury associated with flucloxacillin
 
Br J Clin Pharmacol
 
60
 
:1 81
 
16]. This may explain the long time-lag between the first
marketing of flucloxacillin in the 1970s and the first
reports of its idiosyncratic hepatotoxicity in the mid
1980s.
After a large number of individual case reports of
flucloxacillin-associated cholestatic liver disease
appeared between 1982 and 1993, the association was
confirmed by two formal epidemiological studies, which
provided a frequency estimation of flucloxacillin-asso-
ciated cholestatic liver disease of about 7 per 100 000
first-time users [15, 16]. The current follow-up study
yielded a similar risk estimate of 8.5 per 100 000 users.
This study relates only to cases of cholestatic liver
disease, whereas other forms of liver disease that may
be drug-induced were not studied. As in the previous
studies oxytetracycline was chosen as a comparison drug
because it is a frequently prescribed antibiotic and it has
rarely been reported to cause cholestatic hepatitis [15,
16]. Additionally we also determined the risk of devel-
oping cholestatic liver disease of unknown origin 46–
90 days after exposure to flucloxacillin, i.e. at a time
when we assumed that exposure to flucloxacillin was
much less likely to be the cause of liver disease. However,
a latency time of more than 45 days may be possible in
rare cases, and our study does not exclude the possibility
that cholestatic liver disease was caused by flucloxacillin
in one or more of the five patients where the diagnosis
was made between 46 and 90 days after exposure.
Age over 55 years, female sex and a treatment dura-
tion longer than 14 days have previously been proposed
as risk factors for flucloxacillin-induced liver disease
[13, 22]. The current study estimated a six-fold higher
risk of cholestatic liver disease after flucloxacillin in
patients aged 60 years and older compared with younger
patients. By contrast, female sex was not clearly identi-
fied as a risk factor, and only one case of cholestasis
occurring 1–45 days after flucloxacillin use, and two
cases occurring 46–90 days thereafter had a treatment
duration of more than 14 days.
We did not detect any material changes in the fre-
quency of first-time prescriptions of flucloxacillin in this
UK population-based study between 1991 and 2000.
Following the large number of publications in the early
1990s concerning the risk of flucloxacillin-induced liver
injury, the UK regulatory authority only published a
single warning concerning this issue in 1992 [19]. By
comparison the use of flucloxacillin decreased by about
30% after 1994 in Australia, and this was presumably
the result of a range of initiatives and interventions that
were implemented concurrently and repeatedly over
several years, including a governmental restriction of
the indication for flucloxacillin use to severe infections,
changing the product information, stopping of advertis-
ing and recommending cephalexin and erythromycin as
alternative treatments [4, 18]. The risk of drug-induced
cholestatic liver disease for these alternative drugs has
been estimated to be lower, i.e. about 3.6 and 2.0 per
100000 users for erythromycin and cephalexin, respec-
tively [23, 24]. Dicloxacillin is another halogenated
isoxazolyl penicillin that is used as oral treatment for 
 
S.
aureus
 
 infections in the United States, and that was
introduced onto the Australian market in 1997 to pro-
vide another alternative to flucloxacillin [25]. It has been
reported to have a similar efficacy in soft tissue infec-
tions to flucloxacillin [26, 27], but is not marketed in the
UK. In previous publications it was stated that there are
fewer spontaneous reports of liver disease related to
dicloxacillin as compared with flucloxacillin, and that
the risk may be lower [4, 22, 25]. The question of the
comparative hepatotoxic risk of flucloxacillin and
dicloxacillin is highly relevant to public health. How-
ever, in the current absence of formal population-based
epidemiological studies investigating the risk of liver
disease associated with dicloxacillin, differences in the
reporting frequency of adverse reactions for flucloxacil-
lin and dicloxacillin cannot be ruled out as the reason
for the higher number of reports of liver disease after
flucloxacillin use.
We noted that in the previous epidemiological study
covering the period from 1985 to 1991, flucloxacillin
was diagnosed by the treating physician as the cause of
liver disease in only two out of 10 cases, and in one of
those two only after flucloxacillin rechallenge with sub-
 
Figure 1
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sequent recurrence of jaundice [16]. By contrast, in the
current study that included cases from 1992 to 2002 we
identified such an explicit flucloxacillin attribution in
eight out of the 14 cases that occurred 1–45 days after
flucloxacillin where we received detailed patient
records. This finding may well reflect an increased
awareness of flucloxacillin’s potential hepatotoxicity
amongst physicians in the UK, who nevertheless con-
tinue to use flucloxacillin as a first-line treatment for
soft-tissue infections caused by 
 
S. aureus
 
 [20]. Though
one case of cholestatic liver disease per 12 000 first-time
users may be considered to be a relatively rare event, it
must be taken into account, that the risk is apparently
higher in older patients, that flucloxacillin-induced liver
disease is a potentially irreversible and lethal disease [5,
7, 17], and that the cases identified in this study only
represent a small proportion of the absolute number of
cases that occur each year in the UK, where flucloxacil-
lin is a frequently used drug with about two million
prescriptions per year [19].
 
The presented study was entirely investigator-originated
and not funded by a third party. Dr Russmann is
supported by a Merck Sharp & Dohme International
Fellowship in Clinical Pharmacology. We are indebted
to the general practitioners who contribute information
 
to the GPRD for their continuing effort and cooperation.
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Abstract
Context: There is concern that a new transdermal contraceptive patch containing ethinyl estradiol (EE) and the progestin norelgestromin
increases the risk for venous thromboembolism (VTE) compared to previously marketed oral contraceptives (OCs).
Objective: Quantitative information was obtained on the risk of nonfatal VTE in women using the contraceptive patch in comparison to
women using OCs, norgestimate (either monophasic or triphasic) and 35 Ag EE (norgestimate-35), an OC that has been marketed for over
a decade.
Design, Setting and Participants: Nested case-control design based on information from PharMetrics, a US-based company that collects
and organizes information on claims paid by managed care plans. The study was nested among all women aged 15 to 44, who started either
the contraceptive patch or norgestimate-35 after April 1, 2002. Cases were women with current use of one of these two study drugs and a
documented diagnosis of VTE in the absence of identifiable clinical risk factors (idiopathic VTE). Up to four controls were matched to each
case by age and calendar time.
Main Outcome Measures: Odds ratios (ORs) comparing the risk of nonfatal VTE in new users of the two contraceptives and incidence rates
of nonfatal VTE for new users of each of the study contraceptives.
Results: We identified 68 newly diagnosed, idiopathic cases of VTE in the study population. In the case-control analysis, the OR comparing
the contraceptive patch to norgestimate-35 was 0.9 (95% CI 0.5–1.6). The overall incidence rate for VTE was 52.8 per 100,000 women-years
(95% CI 35.8–74.9) among users of the contraceptive patch and 41.8 per 100,000 women-years among users of norgestimate-35 (95% CI
29.4–57.6), and the age-adjusted VTE incidence rate ratio (IRR) for current use of the contraceptive patch vs. norgestimate-35 was 1.1 (95%
CI 0.7–1.8).
Conclusions: The risk of nonfatal VTE for the contraceptive patch is similar to the risk for OCs containing 35 Ag ethinylestradiol
and norgestimate.
D 2006 Elsevier Inc. All rights reserved.
Keywords: Contraceptive patch; Oral contraceptives; Venous thromboembolism1. Introduction
The combination transdermal contraceptive patch has
been marketed since 2002. This transdermal patch contains
0.75 mg ethinyl estradiol (EE) and 6 mg of the progestin
norelgestromin (the active metabolite of norgestimate) and
releases on average 20 Ag of EE and 150 Ag of
norelgestromin into the systemic circulation per 24 h.
According to a recent statement by the US Food and Drug
Administration (FDA) in a press release dated November0010-7824/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2006.01.001
4 Corresponding author. Tel.: +1 781 862 6660; fax: +1 781 862 1680.
E-mail address: sjick@bu.edu (S.S. Jick).10, 2005, bWomen who use the transdermal patch are
exposed to about 60 percent more total estrogen in their
blood than if they were taking a typical birth control pill
containing 35 A g of estrogen Q [1]. A pharmacodynamic
study found that the maximal blood level (peak blood level)
of EE is about 60% lower with the patch than with a birth
control pill containing 30 Ag EE [2]. The new bold warning
in the approved product labeling for the contraceptive patch
states, bHowever, it is not known whether there are changes
in the risk of serious adverse events based on the differences
in pharmacokinetic profiles of EE in women using the
transdermal patch compared with women using oral contra-
ceptives (OCs) containing 35 A g of EE Q [1].
S.S. Jick et al. / Contraception 73 (2006) 223–228224Oral contraceptives containing estrogen–progestin com-
binations have been associated with an increased risk of
deep vein thrombosis and subsequent pulmonary embolism,
collectively referred to as venous thromboembolism (VTE)
[3–8]. The absolute risk of venous thrombosis has been
reported to increase from a baseline risk of less than 1 per
10,000 women-years to 3 to 4 per 10,000 women-years
during use of OCs. [7].
In the premarketing clinical trials of the transdermal
patch, one case of idiopathic VTE and one case of VTE after
surgery were diagnosed in 3330 users with a cumulative
treatment duration of about 1800 years (22,176 cycles) [9].
However, the low number of users in the clinical trials
limited a precise risk estimate of this uncommon adverse
event and a reliable quantitative comparison with other OCs.
We conducted a study that compared the risk of nonfatal
VTE in women using the transdermal patch to that of
women using monophasic or triphasic norgestimate-
containing OCs with 35 Ag of EE (norgestimate-35), which
have been marketed for over a decade.2. Methods
2.1. Data resource
Data for this study were derived from the PharMetrics
database. PharMetrics is a US-based, ongoing longitudinal
database with information on about 55 million people going
back as far as 1995. The database is made up of data
contributed by managed care health plans throughout the
United States and contains information on paid claims for
pharmaceuticals, medical diagnoses and procedures as well
as demographic information such as patient’s year of birth,
gender and enrollment details for each subject in the
database. Drug prescriptions are coded using the National
Drug Code provided by the US FDA. Each drug claim is
entered as a separate entry and includes information on the
specific entity dispensed, the date of dispensing, the
quantity dispensed and the length of the supply. All
diagnoses are coded using the ICD-9 coding system.
Procedure codes are also included in the database coded
using the CPT-4 system. All events described above are
noted with the date on which the initial service was
delivered. Additional codes describe other aspects of the
patient’s condition at the time of the hospitalization.
The methods applied in this study were similar to those
previously described for the study of contraceptive safety
[5,6]. The present study was designed to take into account
the evaluation of a recently marketed drug and the use of a
comparison drug, which has been marketed for over a
decade, since no other more recently marketed OC was
available. We required that all cases and controls be new
users of either study drug after April 1, 2002, when the
transdermal patch was first marketed. Important variables
that were controlled in the design were (1) age, since users
of the new drug may have a different age distribution thanusers of the older comparison drug; and (2) calendar time
(i.e., the date of diagnosis), since the two contraceptives will
have highly different usage characteristics in relation to
calendar time. We also explored duration of use, which may
be correlated with both drug use and the risk of VTE.
2.2. Base population
We conducted a case-control study nested in the
population of users of the transdermal patch and norgesti-
mate-35 OCs, aged 15 to 44 in the PharMetrics database. All
subjects were required to have filled at least one new
prescription for a study drug after April 1, 2002, the date
that the transdermal patch was first marketed in the United
States. Follow-up medical information was available as far
forward as March 31, 2005.
As a first step, we organized the PharMetrics data files
sent to us into individual patient records. This enabled us to
create a comprehensive chronological record for each
patient that contained information on all drugs prescribed,
diagnoses and procedures, both inpatient and outpatient. To
assess the eligibility of each potential case and control, the
authors conducted a review of each individual patient
computer record with the particular study contraceptive
identity masked. Agreement on inclusion of women as cases
or controls was achieved by consensus without knowledge
of contraceptive exposure.
2.3. Cases
Cases were women aged 15 to 44 years old who were
current users of the transdermal patch or norgestimate-35
and who had a first-time recorded claim for a clinically
diagnosed deep vein thrombosis or pulmonary embolism
with hospitalization, a visit to the emergency room or
positive indication of VTE from diagnostic test results, and
who subsequently received prolonged anticoagulation ther-
apy. Cases were included if the diagnosis of VTE was
recorded for the first time after April 1, 2002. A requirement
for inclusion was that there were at least 6 months of
medical history prior to the diagnosis (index date). In
addition, in order to determine when subjects started using
the study contraceptive, we required that there be at least 4
months of history in their claims record before the first
recorded study contraceptive. The 4-month period is based
on the finding that contraceptive prescriptions in the
PharMetrics database are written for no longer than 3 months
at a time. Thus, a window of at least 4 months provided
assurance that the first identified prescription is a new
prescription and not a refill of an existing prescription. The
case had to be currently exposed to one of the study drugs.
Exposure was determined from the prescription claims data
prior to the date of diagnosis of VTE (index date). Current
exposure was defined as having a recorded claim for a study
contraceptive prescription whose filled use extended to
within 30 days before the index date or beyond the index
date. Long-term anticoagulation must have been started
promptly, and no estrogen-containing contraceptive could
Table 1
Characteristics of cases and controls
Characteristic Cases (n =68) Controls (n =266)
n % n %
Age
15–29 27 40 104 39
30–39 26 38 103 39
40–44 15 22 59 22
Index year a
2002 8 12 31 11
2003 33 49 130 50
2004 22 32 85 31
2005 5 7 20 7
a Year of diagnosis of the VTE event.
able 2
dds ratio for VTE comparing users of contraceptive patch to users of
orgestimate-35
xposure Cases Controls Odds ratioa 95% CI
n % n %
orgestimate-35 37 54 139 52 1.0 Reference
ontraceptive patch 31 46 127 48 0.9 0.5–1.6
a Conditional on age, index date.
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clinical diagnosis of VTE.
Potential cases were excluded from the case group if
important clinical risk factors for VTE were present in the
3 months prior to the index date [10]. These included
significant lower limb injury, major surgery, severe trauma
or pregnancy. Subjects with any history of cancer (other
than nonmelanoma skin cancer), renal failure, chronic
cardiovascular disease, or inflammatory or autoimmune
conditions were also excluded.
2.4. Controls
Up to four women who did not have a diagnosis of VTE
were matched to each case by year of birth and the index
date of the case (calendar time). When more than four
matched controls were available for a case, we used random
selection to select four controls. As with cases, all controls
were required to be current users of one of the study
contraceptives, to have at least 6 months of enrollment in
their health plan prior to the index date (the event date of
their matched case), to have started their study contraceptive
use after April 1, 2002, and to have at least 4 months
of history in their claims record before the first recorded
study drug prescription to confirm that they were new
users. The exclusion criteria applied to cases were also
applied to controls.
2.5. Statistical methods
We analyzed the matched case-control data using
conditional logistic regression. Duration of contraceptive
use prior to the index date and switching from a different
hormonal contraceptive were considered as potential con-
founders, as well as number of physician and emergency
room visits in the 6 months prior to the index date.
We analyzed the cohort data to estimate incidence rates
and 95% confidence intervals. Current person-time was
accumulated from the first study drug prescription to the last
prescription plus 45 days. If there was a gap in the
prescription fill dates of greater than 100 days, the person-
time accumulation stopped at the last prescription before the
gap, plus 45 days; person-time accumulation then resumedat the next record of a prescription for a study drug. We
estimated incidence rate ratios (IRRs) using Poisson
regression. We examined possible effect modification by
including multiplicative interaction terms in the model, and
we compared the fit of nested models using likelihood ratio
testing [11].
Duration of contraceptive use was defined as the time
interval (in months) from the first use of the study
contraceptive to the index date. A subject was defined as
a switcher if there was a recording for a different hormonal
contraceptive product at any time in the patient’s record that
preceded the use of the study contraceptive.
Calculations were performed using SAS release 8.02
(SAS Institute, Cary, NC) and Stata release 8.2 (StataCorp
LP, College Station, TX).
This study was exempt from review by the Boston
University Medical Center Institutional Review Board.3. Results
We identified 68 cases of VTE and 266 controls (women
without VTE), matched by year of birth and index date.
Among the 68 cases of idiopathic VTE, there were 31 among
women currently exposed to the transdermal patch and
37 currently exposed to norgestimate-35. Fifty-seven cases
were hospitalized, 38 (67%) with a diagnosis of pulmonary
embolism and 11 were diagnosed as outpatients, only
4 (36%) with a diagnosis of pulmonary embolism. All
11 cases in the outpatient setting were prescribed warfarin
and 9 cases also received low-molecular-weight heparin.
Characteristics of the cases and controls are listed in
Table 1 and their exposure to the transdermal patch or
norgestimate-35 is summarized in Table 2. The unadjusted
matched odds ratio (OR) for VTE for the transdermal patch
vs. norgestimate was 0.9 (95% CI 0.5–1.6) (Table 2). After
adjusting for duration of exposure, the OR remained 0.9. A
history of switching from another hormonal contraceptive
had no effect on the OR, nor did restricting the analysis to
women who were hospitalized for VTE, or adjusting for the
frequency of physician’s office or emergency room visits
during the 6-month period before the index date.
In the study population, there were 215,769 women
who satisfied all the conditions for inclusion in this study.
These women contributed an estimated 147,323 women-
years of current exposure to the study contraceptives
(58,752 women-years for the transdermal patch andT
O
n
E
N
C
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overall incidence rate for VTE in the study population
was 52.8 per 100,000 women-years (95% CI 35.8–74.9)
among users of the contraceptive patch and 41.8 per
100,000 women-years among users of norgestimate-35
(95% CI 29.4–57.6). Adjusted for age, the VTE IRR for
current use of the transdermal patch vs. norgestimate-35 was
1.1 (95% CI 0.7–1.8). The data did not provide evidence for
effect modification by age (p=.10). Regardless of which
contraceptive was used, the incidence of VTE increased
with increasing age. The incidence per 100,000 women-
years was 26.7 (95% CI 17.6–38.9) among women aged
15–29 years, 67.2 (95% CI 43.9–98.5) among women aged
30–39 years and 197 (95% CI 110–326 per 100,000 women-
years) among women aged 40–44 years (pb .001 for test
of trend).4. Discussion
Spontaneous reports of thrombosis in users of the
transdermal patch have raised major public concern about
its safety. In contrast to OCs, no gastrointestinal or hepatic
first-pass metabolism occurs after transdermal application,
and for postmenopausal estrogen therapy it has been
suggested that this difference may result in a lower clinical
risk of VTE with transdermal estradiol than oral estrogen
[12,13]. So far, no formal studies have been available to
investigate whether these spontaneous reports reflect a
higher risk of VTE or indeed whether the transdermal
contraceptive patch may have a lower risk of VTE than
comparable OCs.
The findings of this study provide evidence that the risk
of nonfatal VTE with subsequent long-term anticoagulation
is not higher in current transdermal contraceptive patch
users compared to current users of the norgestimate-35 OC
(OR 0.9, 95% CI 0.5–1.6; IRR 1.1, 95% CI 0.7–1.8). In the
current study, the risk of VTE in users of the transdermal
patch was compared to the risk in users of norgestimate-35
because norelgestromin is the active metabolite of norges-
timate, the progestin released by the transdermal patch. This
methodology is the most efficient design to study risk
differences in relation to the route of administration and also
allows for the important comparison to a drug that has been
marketed for more than a decade.
The current epidemiologic study used a case-control
design, which has often been used in the past to study the
safety of hormonal contraceptives [3,5,6,14,15]. A nested
case-control study design is standard for drug safety studies
for evaluating contraceptive safety since it insures compa-
rability between cases and the comparison group at the time
of the case event [16]. As in prior studies, age and calendar
time were closely controlled, i.e., the controls were matched
to cases on year of birth, and the date from which exposure
was determined (the index date) was identical in cases and
controls. This procedure equalizes the potential influence of
age and calendar time on the relative effect of the twocontraceptives. There is, however, one feature of this study
that differs from prior studies. Whereas prior studies
compared contraceptives that had been marketed for many
years, the current study involves the comparison of an
estrogen-containing contraceptive (the transdermal patch)
that has been marketed for only 3 years with norgestimate-
containing OCs that have been available for more than a
decade. In the PharMetrics database, new use of the
transdermal patch increased markedly over the first few
years after April 2002, whereas that of norgestimate-35
decreased over the same time period. Among women
included in this study, the proportion who started using
the transdermal patch rose progressively from 23% in 2002
to 55% in 2004, whereas the proportion of norgestimate-35
users fell correspondingly. We have controlled for this
difference by including only women with new use of one or
the other study contraceptives after April 1, 2002, the date
that the transdermal patch became available. Although it is
possible that norgestimate-35 may have been used by cases
or controls in the distant past, previous studies have
convincingly demonstrated that only current use is relevant
to the risk of VTE, and thus this possible difference in the
past use of the two study drugs is unlikely to have had a
material effect on the results obtained [3].
We limited the study to nonfatal outcomes because the
PharMetrics database does not capture deaths that occur
outside a health care facility. However, fatal cases of VTE
during use of hormonal contraceptives have been reported to
represent only a small proportion of all VTE cases, and
failure to identify them in this study is unlikely to have
materially distorted the findings [5]. We also excluded
patients with chronic medical conditions such as cancer,
coronary artery disease and autoimmune disease. Although
these were not commonly observed in this generally healthy
young population of contraceptive users, the exclusion of
such patients from the study population limits concerns
about selective prescribing of the study drug based on the
presence of clinical risk factors.
As in any epidemiology study, there may be some
misclassification of cases. Any such misclassification would
be nondifferential since we identified cases and controls
without knowledge of the contraceptive to which they had
been exposed. Nondifferential misclassification of a dichot-
omous variable tends to bias results toward the null.
However, since we used the same operational definition of
VTE in this study as in many other studies that we have
carried out where differences in risk of VTE have been
found, we consider this to be a minor issue [5,6,10,14].
We could not evaluate the effect of smoking in the
current study since it is not regularly recorded in the
PharMetrics database. However, smoking is believed to
increase primarily the risk of arterial cardiovascular events
in users of OCs, but not the risk of VTE, and smoking has
not been a material confounder in previous studies
comparing the association between OCs and VTE
[5,6,15,17,18]. Also, neither height nor weight was recorded
S.S. Jick et al. / Contraception 73 (2006) 223–228 227in the current study. Although body mass index (BMI) is
independently associated with a modestly increased risk for
VTE, BMI has not confounded the association between use
of hormonal contraceptives and VTE in prior studies
[3,5,6,14]. Furthermore, when we evaluated the ICD-9
diagnosis for obesity we did find that obesity was associated
with an increased risk ratio for VTE (OR=2.3), but
inclusion of obesity in the model with exposure did not
materially change the effect of exposure, providing addi-
tional reassurance that obesity is not an important con-
founder in this study. Although the ICD code is not an ideal
proxy for obesity, we believed that the diagnosis would
most often be used in the most obese women. Obesity was
associated with VTE as it has been in past studies [3,5,6,14],
yet it did not confound the effect of the contraceptives we
compared. This indicates that the ICD code was probably a
reasonable proxy given that the information was limited. If
there were a strong tendency for the patch to be
preferentially prescribed to thinner women, it is possible
that the OR for VTE with the patch calculated in this study
is an underestimate of the true risk.
The effect of duration of use of contraceptives could not
be fully explored since the study period encompassed only
3 years and a substantial proportion of contraceptive users
had used them for less than 1 year. Further studies over time
will allow for a more comprehensive evaluation of the effect
of longer duration of use.
Samples of the transdermal patch were distributed in the
first years that the drug was marketed. This would not have
been true of norgestimate-35 during the study period. We
cannot rule out some influence of this difference that applied
to both cases and controls, but the nature of the results was
such that any effect is likely to have been modest.
Over 215,000 women exposed to one of the study drugs
in our study population provided information on the
clinically important question of the risk of VTE in relation
to the transdermal patch. Because of the prospective nature
of data collection, the information on exposure was
collected before the outcome had occurred, all eligible
patients with the outcome were included, and the
likelihood of correct diagnoses of VTE was increased by
the documentation of long-term use of anticoagulants. We
were able to tightly control potential confounding due to
age and calendar time. The rate of VTE associated with
combination contraception use in this study was higher
than that found in previous studies [5,6], but this study
encompassed women up to age 44, whereas the earlier
studies included only women up to age 39. This difference
would at least partially account for the somewhat higher
rate of VTE in this study.
In summary, although higher mean circulatory levels of
EE have been reported among users of the contraceptive
patch compared to users of combined OCs, our results
indicate that the risk of nonfatal idiopathic VTE among new
users of the transdermal patch is similar to that of new users
of norgestimate-35.Acknowledgments
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Abstract
Context: Previous studies have reported that users of the b third-generation Q oral contraceptives (OCs) containing the progestins gestodene
and desogestrel have about twice the risk for venous thromboembolism (VTE) compared to users of older OCs containing levonorgestrel.
Estimates of the risk for VTE among users of norgestimate-containing OCs compared to other OCs, however, are lacking.
Objective: The purpose of this study is to obtain quantitative information on the risk of nonfatal VTE in women using OCs containing either
norgestimate or desogestrel in comparison with women taking OCs containing levonorgestrel.
Design, Setting and Participants: Based on information from PharMetrics, a United States-based company that collects and records
information on claims paid by managed care plans, we used a nested case-control study design to estimate relative risks of nonfatal VTE
among 15- to 39-year-old current users of OCs containing norgestimate with 35 Ag of ethinyl estradiol (EE), desogestrel with 30 Ag of EE or
levonorgestrel with 30 Ag of EE, both monophasic and triphasic preparations, during the period January 2000 to March 2005. Cases were
women with a well-documented VTE of uncertain origin that was diagnosed in current users of a study drug. Up to four controls were closely
matched to each case by age and calendar time, and odds ratios (ORs) were calculated using conditional logistic regression comparing the
risk of VTE among users of the three contraceptives. We also estimated and compared the incidence rates for all three OCs.
Results: Based on 281 newly diagnosed idiopathic cases of VTE and 1055 controls, we found that the adjusted ORs for nonfatal VTE
comparing norgestimate- or desogestrel-containing OC users to users of levonorgestrel-containing OCs were 1.1 [95% confidence interval
(CI), 0.8–1.6] and 1.7 (95% CI, 1.1–2.4), respectively. The incidence rates of VTE were 30.6 (95% CI, 25.5–36.5), 53.5 (95% CI, 42.9–
66.0) and 27.1 (95% CI, 21.1–34.3) per 100,000 woman-years for users of norgestimate-, desogestrel- and levonorgestrel-containing OCs,
respectively. The incidence rate ratios for norgestimate-containing OCs compared to levonorgestrel-containing OCs and desogestrel-
containing OCs compared to levonorgestrel-containing OCs were 1.1 (95% CI, 0.8–1.5) and 2.0 (95% CI, 1.4–2.7), respectively.
Conclusions: The risk of nonfatal VTE among users of desogestrel-containing OCs is significantly elevated compared to that of
levonorgestrel-containing OCs. The risk of VTE in users of norgestimate-containing OCs was closely similar to that of users of
levonorgestrel-containing OCs.
D 2006 Elsevier Inc. All rights reserved.
Keywords: Oral contraceptives; Venous thromboembolism; Odds ratio; Incidence rate ratio1. Introduction
Three reports published in Lancet in 1995 found an
approximately twofold increased risk of venous thrombo-
embolism (VTE) for oral contraceptives (OCs) containing
either desogestrel or gestodene, compared to OCs containing
levonorgestrel [1–3]. Norgestimate-containing OCs, which
are not commonly used in the UK, are among the most0010-7824/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.contraception.2006.02.002
4 Corresponding author. Tel.: +1 781 862 6660; fax: +1 781 862 1680.
E-mail address: sjick@bu.edu (S.S. Jick).commonly prescribed OCs in the Unites States. Reliable
information on the effects of norgestimate-containing OCs
on the risk for VTE has not been published since most of
the earlier studies on the risk of VTE among users of OCs
were conducted in Europe and other countries where
norgestimate-containing OCs are uncommonly prescribed
and information was therefore limited. The question remains
whether the progestin norgestimate is more similar to the
levonorgestrel-containing bsecond-generation Q or to the
desogestrel-containing b third-generationQ OCs with respect
to its effect on the risk of VTE [4]. Since b third-generation Q73 (2006) 566–570
S.S. Jick et al. / Contraception 73 (2006) 566–570 567OCs have been reported to increase the risk of VTE, and
because norgestimate-containing contraceptives are widely
prescribed in the United States, we conducted a study to
compare the risk of nonfatal VTE in users of norgestimate-
containing OCs with 35 Ag of ethinyl estradiol (EE) and,
separately, desogestrel-containing OCs with 30 Ag of EE
(a bthird-generationQ pill used in the United States) to the risk
of nonfatal VTE in users of levonorgestrel-containing OCs
with 30 Ag of EE. This is the first study that we know of
to evaluate the effects on VTE risk of norgestimate- and
desogestrel-containing OCs in the United States.2. Methods
2.1. Data resource
Data for this study were derived from the PharMetrics
database. PharMetrics is a United States-based ongoing
longitudinal database with information on about 55 million
people starting as early as 1995. The database is made up
of data contributed by managed care plans throughout
the United States, and it contains information on paid
claims for pharmaceutical agents, medical diagnoses and
procedures as well as demographic information on all
subjects. Demographic information such as patient’s year
of birth, gender and enrollment details are provided in the
database. Drug prescriptions are coded using the National
Drug Code provided by the U.S. Food and Drug Admin-
istration. Each drug claim is recorded as a separate entry
and includes information regarding the specific entity
dispensed, the date of dispensing, the quantity dispensed
and the length of the supply. All diagnoses are coded using
the ICD-9 coding system. Procedures are also included
in the database coded using the CPT-4 system. All events
described above are noted with the date on which the
initial service was delivered. Additional codes describe
other aspects of the patient’s condition at the time of
the hospitalization.
The methods applied in this study are closely similar to
those we have used extensively in the past for the study of
contraceptive safety [1,5,6].
2.2. Base population
We conducted a case-control study nested in the
population of 15- to 39-year-old users of all norgestimate-
containing OCs with 35 Ag of EE, desogestrel-containing
OCs with 30 Ag of EE or levonorgestrel-containing OCs
with 30 Ag of EE, both monophasic and triphasic
formulations, in the PharMetrics database from 2000 to
2005. All subjects were required to have filled at least one
prescription for a study drug. Medical information was
available until as late as March 31, 2005.
2.3. Study design
As a first step, we organized the PharMetrics data for
each woman into a comprehensive chronological recordcontaining information on all drugs prescribed, diagnoses
and procedures, both inpatient and outpatient for each
patient. The authors conducted a review of each individual
patient’s computer record, with the particular study contra-
ceptive identity masked, to assess the eligibility of each
potential case and control. Agreement on inclusion of
women as cases or controls was achieved by consensus
without knowledge of contraceptive exposure.
2.4. Cases
Cases were women aged 15 to 39 years old, who were
current users of norgestimate-, desogestrel- or levonorges-
trel-containing OCs and had a first-time recorded diagnosis
of deep vein thrombosis or pulmonary embolism at any time
during the study period, followed by long-term anticoagu-
lation. At least 6 months of recorded medical history was
required prior to the diagnosis (index date), and each case
had to be currently exposed to one of the study drugs at the
index date. Current exposure was defined as having a
recorded claim for a study contraceptive prescription whose
filled use extended to within 30 days before the index date
or beyond the index date. Potential cases were excluded
from the case group if well documented; important clinical
risk factors for VTE were present in the 3 months prior to
the index date. These included important lower-limb injury,
invasive surgery, severe trauma or pregnancy. We also
excluded women with any history of cancer (excluding
nonmelanoma skin cancer), renal failure or inflammatory or
autoimmune conditions [1–8]. Finally, we excluded women
with VTE if estrogen-containing contraceptives were
prescribed after the index date, suggesting that the diagnosis
of idiopathic VTE was not confirmed.
2.5. Controls
Up to four women who did not have a diagnosis of
VTE were matched to each case by the year of birth and the
index date of the case. As with cases, all controls were
required to be current users of one of the study contra-
ceptives and to have at least 6 months of enrollment in their
health plan prior to the index date (the event date of their
matched case). All of the exclusion criteria applied to cases
were applied to controls.
2.6. Statistical methods
We analyzed the case-control study data using condi-
tional logistic regression. All models were controlled for age
and calendar time through matching. We also evaluated
the effects of covariates by entering them individually and
collectively into the regression model, including the
exposure variable. History of each of the following potential
risk factors was considered in the analyses: menstrual
disorders, endometriosis, uterine fibroids, hypertension,
hyperlipidemia, type II diabetes, cardiovascular disease
(varicose veins, peripheral vascular disease, unstable angina,
atherosclerosis, dysrhythmias, coagulation defects and
congestive heart failure) and asthma. We also evaluated
Table 1
Characteristics of cases and controls and univariable effects
Characteristics Cases (%),
n =281
Controls (%),
n =1055
OR 95% CI
Age (years)
b20 26 (9) 103 (10) – –
20–29 114 (41) 426 (40) – –
30–39 141 (50) 526 (50) – –
Index year
2000 21 (7) 81 (8) – –
2001 66 (23) 246 (23) – –
2002 66 (23) 251 (24) – –
2003 70 (25) 259 (25) – –
2004 51 (18) 190 (18) – –
2005 7 (2.5) 28 (2.5) – –
Fibroids 4 (1) 7 (b1) 2.0 0.5–7.2
Endometriosis 1 (b1) 8 (b1) 0.4 0.1–3.5
Menstrual disorders 34 (12) 74 (7) 1.8 1.1–2.7
Hypertension 9 (3) 21 (2) 1.6 0.7–3.5
Hyperlipidemia 12 (4) 24 (2) 1.9 0.9–3.9
Cardiovascular disease 5 (2) 8 (1) 2.5 0.8–7.8
Diabetes 8 (3) 6 (b1) 6.1 2.0–19.0
Asthma 13 (5) 31 (3) 1.6 0.8–3.0
Back pain 28 (10) 50 (5) 2.2 1.4–3.7
Any emergency room visits 36 (13) 31 (3) 5.2 3.1–8.7
Any physician visits 43 (15) 94 (9) 1.8 1.2–2.7
Switchers 14 (5) 70 (7) 0.8 0.6–1.2
S.S. Jick et al. / Contraception 73 (2006) 566–570568whether or not there were physician visits in the 90 days
prior to the index date and, separately, emergency room
visits in the 90 days prior to the index date as indicators of
subjects’ general health. Duration of contraceptive use prior
to the index date was considered as a potential confounder
or risk modifier. Duration was defined as the time interval
(in months) from the first use of the study contraceptive to
which they were currently exposed to the index date.
Finally, women were classified as having a recorded history
of switching hormonal contraceptives if they had any claim
for a hormonal contraceptive in the 6 months prior to the
index date that differed from the one to which they were
currently exposed on their index date.
We analyzed the cohort data to estimate incidence rates
of VTE for each study drug. Current person-time was
accumulated from the first study drug prescription to the last
prescription plus 45 days. If there was a gap in the pre-
scription fill dates of greater than 100 days, the person-time
accumulation stopped at the last prescription before the gap,
plus 45 days; person-time accumulation then resumed at the
next record of a prescription for a study drug. Finally, weTable 2
Odds ratio for VTE comparing users of norgestimate- and desogestrel-containing O
Exposure Cases (%), n =281 Controls (%), n =1055
Levonorgestrel 70 (25) 316 (30)
Norgestimate 124 (44) 511 (48)
Desogestrel 87 (31) 228 (22)
a Conditional on age, index date.
b Adjusted for fibroids, endometriosis, menstrual disorders, hypertension, hype
and recent physician visits.calculated crude incidence rate ratios (IRRs) and age-
adjusted IRRs using the Mantel–Haenszel method.
Calculations were performed using SAS release 8.02
(SAS Institute, Cary, NC) and Stata release 8.2 (StataCorp
LP, College Station, TX).
This study was exempt from review by the Boston
University Medical Center’s institutional review board.3. Results
Approximately 1.3 million women in the PharMetrics
database filled at least one prescription for a study OC
during the study period. From this population, we identified
281 cases of idiopathic VTE and 1055 controls (women
without VTE) matched by year of birth and index date.
Characteristics of the cases and controls are listed in Table 1.
The risk of VTE increased with increasing age, and cases
were significantly more likely than controls to have
diabetes, menstrual disorders and back pain. They were
also more likely to have had recent emergency room visits
or outpatient visits to a physician.
Norgestimate-containing OCs were the most widely
used OC in this population. Five hundred eleven controls
(48%) were currently exposed to norgestimate-containing
OCs compared to 316 users (30%) of levonorgestrel-
containing OCs and 228 users (22%) of desogestrel-
containing OCs. Among the 281 cases of idiopathic VTE,
124 (44%) were currently exposed to norgestimate-contain-
ing OCs, 70 (25%) were exposed to levonorgestrel-contain-
ing OCs at the index date and 87 (31%) were currently
exposed to desogestrel-containing OCs. The unadjusted odds
ratios (ORs) for VTE controlling for the matching factors
only were 1.1 [95% confidence interval (CI), 0.8–1.5],
comparing norgestimate-containing OCs to levonorgestrel-
containing OCs, and 1.7 (95% CI, 1.2–2.4), comparing
desogestrel-containing OCs to levonorgestrel-containing
OCs. When we included the covariates that were indepen-
dently associated with VTE in the model, the ORs and 95%
CIs did not change (Table 2).
We also evaluated the effect of duration of OC use,
which was neither a confounder nor an effect modifier of the
relation between the study OCs and VTE. The median
durations of use for users of norgestimate-containing OCs
were 7.8 months for cases and 7.3 months for controls. For
users of desogestrel-containing OCs, the median durations
were 8.7 and 7.6 months for cases and controls, respectively,Cs to users of levonorgestrel-containing OCs, adjusted and unadjusted ORs
ORa 95% CI Adjusted ORb 95% CI
1.0 Reference 1.0 Reference
1.1 0.8–1.5 1.1 0.8–1.5
1.7 1.2–2.4 1.7 1.2–2.4
rlipidemia, CVD, diabetes, asthma, back pain, recent emergency room visits
S.S. Jick et al. / Contraception 73 (2006) 566–570 569and for users of levonorgestrel-containing OCs, the median
durations were 8.5 and 8.2 months, respectively. Lastly, we
evaluated the effects of switching OCs some time in the
6 months prior to the index date. Switching from another
OC to the current OC was not a confounder of the OC
VTE relation.
The incidence rate of VTE in norgestimate-containing
OC users was 30.6 per 100,000 woman-years (95% CI,
25.5–36.5). For desogestrel-containing OC users, the
incidence rate was 53.5 per 100,000 woman-years (95%
CI, 42.9–66.0), and for levonorgestrel-containing OC users,
the rate was 27.1 per 100,000 woman-years (95% CI, 21.1–
34.3). The IRR for use of norgestimate-containing OCs
compared to levonorgestrel-containing OCs was 1.1 (95%
CI, 0.8–1.5). For desogestrel-containing OCs compared to
levonorgestrel-containing OCs, the IRR was 2.0 (95% CI,
1.4–2.7). These IRRs were not materially changed when
age was taken into account.4. Discussion
The results of this study indicate that the risk of nonfatal
VTE is similar in users of norgestimate- and levonorgestrel-
containing OCs and significantly higher among current
users of desogestrel-containing OCs compared to current
users of the levonorgestrel-containing OCs [OR, 1.7 (95%
CI, 1.1–2.4); IRR, 2.0 (95% CI, 1.4–2.7)], and these findings
are consistent with the results of earlier studies [1–5]. As in
prior studies, age and calendar time were closely controlled,
that is, the controls were matched to cases by year of birth,
and the date from which we evaluated exposure to the study
drugs was identical in cases and controls.
To date, studies that evaluated the effects of different OC
products in relation to VTE risk did not have enough
information on women exposed to norgestimate-containing
pills to be able to assess the effects of these OCs. Therefore,
there has been some question as to the thrombogenic effects
of these formulations compared to other OC preparations.
This study provides evidence that norgestimate-containing
OCs have a risk of VTE that is comparable to that of
levonorgestrel-containing OCs and is lower than the risk in
desogestrel-containing OCs. Also, this study was able to
provide additional evidence that users of desogestrel-
containing OCs have an increased risk of VTE compared
to users of levonorgestrel-containing OCs [1–5].
The consistency of this result with previous findings
provides reassurance that the quality of the data used in
this study is satisfactory for the conduct of this type of drug
safety study.
In an earlier study using the PharMetrics database, we
evaluated the risk of nonfatal VTE in users of the
contraceptive patch compared to users of norgestimate-
containing OCs. In that study, we found no increased risk
in the users of the patch (OR 0.9) [9]. However, there has been
uncertainty as to whether the norgestimate-containing OCusers were also at an elevated risk for VTE compared to users
of levonorgestrel-containing OCs, a bsecond-generationQ OC
[4]. The present study provides evidence that the risk of VTE
in users of the patch is similar to that in users of either
levonorgestrel- or norgestimate-containing OCs.
We included women aged 15 to 39 years in this study
(which differs from the recently published study of the con-
traceptive patch where we included women up to 44 years
old [9]) so that the results would be comparable to those in
earlier studies [1,5,6].
In this investigation, we studied the effect of OCs on
the risk of nonfatal VTE. We limited the study to nonfatal
outcomes because the PharMetrics database does not
capture deaths that occur outside a healthcare facility, and
by design, we required evidence of anticoagulation therapy
after the VTE event. Fatal cases of VTE in women taking
contraceptives have been reported to represent a small
proportion of all cases. Failure to identify fatal VTE in this
study is unlikely to have materially distorted the finding
because the OR for nonfatal and fatal VTE comparing third-
to second-generation OCs was similar in a previously
published study [1].
The database has certain limitations that merit discussion.
We were not able to obtain original clinical records to
validate the VTE diagnoses in the cases. However, we were
able to review all computer-recorded information for each
case, and we applied strict criteria to the case definition.
Cases were required to have diagnoses and procedures that
were consistent with a confirmed VTE diagnosis, and they
must have been treated with long-term anticoagulation
therapy, a regimen that would not be prescribed to otherwise
healthy young women in the absence of a thrombosis. In a
prior study using a UK general practice database where
we did not send for records [5], we found a result similar to
that of the current study and to that of an earlier study
conducted using the UK database where we did perform
record validation [1].
We excluded women with a prior VTE and women with
chronic medical conditions such as cancer, inflammatory
disease, autoimmune disease or renal failure in order to
avoid potential confounding due to preferential prescribing
of one contraceptive compared to the other because of
existing clinical risk factors for VTE. We also excluded
women with recent surgery, major trauma, lower limb injury
or pregnancy because they are known to be strong risk
factors for VTE. We could not evaluate potential confound-
ing due to smoking since it is not regularly recorded in the
PharMetrics database. Also, neither height nor weight was
recorded. Although we cannot rule out the possibility that
these factors were confounders in these data, it should be
noted that smoking was not associated with VTE when OCs
containing high doses of estrogen were used [7,8,10]. More
recently, a modest association between smoking and VTE
has been found in some studies involving low-dose
estrogen-containing contraceptives. However, it has not
been a material confounder in these studies [1–3,5].
S.S. Jick et al. / Contraception 73 (2006) 566–570570Similarly, while BMI is independently associated with a
modest increased risk for VTE, it has also not confounded
the association between second- or third-generation OCs
and VTE in prior studies [1–3,5]. Although there is no
information on BMI in these data, there is an ICD code for
obesity that we evaluated in relation to the effect on the risk
of VTE in this study. There was an increased risk of VTE
among those with a diagnosis of obesity (OR, 1.7; 95% CI,
0.8–3.6), but a diagnosis of obesity did not confound the
relation between the study OCs and VTE.
Over 1 million women exposed to one of the study drugs
in this population provided information for this report. This
study was not subject to exposure recall bias that can be a
concern with interview-based case-control studies. The
study was population-based with information on exposure
collected prospectively before the outcome occurred. All
eligible patients with the outcome were included, and
diagnoses were made together with the recording of long-
term use of anticoagulants. We were also able to tightly
control potential confounding due to age and calendar time.
The findings of this study provide the first substantial
evidence that norgestimate-containing OCs confer a risk
for nonfatal VTE similar to that of the levonorgestrel-
containing OCs, and they add additional evidence that
OCs containing desogestrel are associated with a higher
risk of VTE compared to norgestimate- and levonorgestrel-
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Nonsteroidal Antiinflammatory Drugs and Acute
Myocardial Infarction in Patients with No Major Risk Factors
Hershel Jick, M.D., James A. Kaye, M.D., Dr.P.H., Stefan Russmann, M.D., and Susan S. Jick, D.Sc.
Study Objective. To assess the risk of long-term use of five nonsteroidal
antiinflammatory drugs (NSAIDs)—rofecoxib, celecoxib, ibuprofen,
naproxen, and diclofenac—in relation to acute myocardial infarction.
Design. Five separate nested case-control studies, one for each NSAID,
designed to minimize important biases present in other observational
studies.
Setting. University-affiliated research program.
Data Source. The United Kingdom General Practice Research Database
(GPRD).
Measurements and Main Results. We identified all people in the GPRD aged
30–79 years who had a first recorded prescription for rofecoxib, celecoxib,
ibuprofen, naproxen, or diclofenac after January 1, 1999.  Cases of newly
diagnosed, first-time acute myocardial infarction were then identified from
the study population, along with matched control subjects.  Relative risk
estimates for acute myocardial infarction in patients with no recorded
major clinical risk factors for acute myocardial infarction were determined
for each NSAID according to receipt of 2–4, 5–9, 10–19, or 20 or more
prescriptions compared with receipt of only 1 prescription.  Results were
adjusted for relevant variables possibly related to the risk for acute
myocardial infarction.  No material elevation of risk according to the
number of prescriptions received for ibuprofen or naproxen was noted.
However, a substantial increased risk similar to that found in clinical trials
was noted in patients who received 10 or more prescriptions for rofecoxib,
celecoxib, or diclofenac.
Conclusion. Extensive use of rofecoxib, celecoxib, and diclofenac increases
the risk of acute myocardial infarction, but similar use of ibuprofen and
naproxen does not.
Key Words: cyclooxygenase 2, COX-2, nonsteroidal antiinflammatory drugs,
NSAIDs, acute myocardial infarction, AMI, observational study, rofecoxib,
celecoxib, diclofenac.
(Pharmacotherapy 2006;26(10):1379–1387)
Three long-term randomized clinical trials
have produced information about the risk of
myocardial infarction and other cardiovascular
events associated with use of the cyclooxygenase
2 (COX-2)–selective nonsteroidal antiinflam-
matory drugs (NSAIDs) rofecoxib and celecoxib.1–3
One of these studies evaluated patients with
rheumatoid arthritis who were randomly assigned
to treatment with rofecoxib or the nonselective
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NSAID naproxen,1 and the other two studies
evaluated patients with a history of colon polyps
who were randomly assigned to treatment with a
COX-2 inhibitor or placebo.2, 3 Each of these
trials found an important elevation in the risk of
myocardial infarction in particular or a group of
serious cardiovascular adverse events collectively
among people receiving these COX-2 inhibitors
compared with those receiving placebo or naproxen.
Aspirin was reported to be protective against
myocardial infarction in observational studies4, 5
published in the early 1970s, and a protective
effect subsequently was demonstrated repeatedly
in randomized trials.6, 7 However, none of the
nonaspirin NSAIDs available before the
marketing of COX-2 inhibitors has been
subjected to long-term clinical trials; therefore,
judgment as to their effect on the risk of
myocardial infarction must necessarily be derived
from observational studies.  A systematic review
of more than a dozen observational studies that
evaluated a large group of NSAIDs (including
most recently COX-2 inhibitors) in relation to
the risk of myocardial infarction was recently
published.8 The authors reported the following
findings:  the pooled relative risk (RR) for
patients with myocardial infarction compared
with control subjects for all current NSAID users
combined compared with nonusers was 1.09
(95% confidence interval [CI] 1.06–1.13); no RR
greater than 1.5 was found for any of the
individual NSAIDs when all users were
considered; and a “statistically increased risk”
was found for diclofenac (RR ~1.4) and rofecoxib
(RR ~1.4).  The interpretation of such observa-
tional studies involves careful consideration of
numerous factors that influence the risk of
myocardial infarction and that may also affect the
patterns of usage of NSAIDs in general and
certain NSAIDs in particular.
In this study of five NSAIDs and the risk of
myocardial infarction, we employed a study
design not previously used in an attempt to
minimize important biases that may have been
present in previous observational studies.  Our
study was designed to reflect the major findings
reported from randomized trials in that we
sought to assess the relation of long-term use
(> 10 mo) of rofecoxib, celecoxib, ibuprofen,
naproxen, and diclofenac rather than considering
only current use.  In addition, unlike most
previous studies (trials and observational), we
assessed the risk for acute myocardial infarction
in patients who had no previous recorded
clinically important risk factors for myocardial
infarction.  The study was based on data from the
United Kingdom General Practice Research
Database (GPRD), a database whose completeness
and validity have been repeatedly demonstrated.9
Methods
Base Population
We identified all people aged 30–79 years in
the GPRD who had a first recorded use of
rofecoxib, celecoxib, ibuprofen, naproxen, or
diclofenac after January 1, 1999 (the year
rofecoxib was marketed; celecoxib was first
marketed in 2000).  We conducted five separate
nested case-control studies, one focusing on each
of the five study NSAIDs.  Subjects could be
included in more than one study if they had a
first recorded prescription for more than one
study drug after January 1, 1999.  The study
period ended in September 2005 (although all
practices contributing information to the GPRD
may not have updated their information to that
time).
Cases
For each of the five NSAIDs separately, we
identified all people in the base population with a
first-time Oxford Medical Information System
code or Read code for myocardial infarction after
January 1, 2001, who had at least one prescrip-
tion for the NSAID of interest before their index
date (the date of the first recorded diagnosis of
myocardial infarction) and who had at least 2
years of history recorded in the GPRD before
their index date.  We limited cases to those
diagnosed after January 1, 2001, to ensure that
enough time had passed for study subjects to
have sufficient opportunity to be exposed to any
of the study drugs.  To better isolate the potential
effect of the NSAIDs of interest on the risk of
myocardial infarction, we excluded cases with
any of the following diagnoses more than 1
month before the diagnosis of myocardial
infarction:  ischemic heart disease (angina, previous
myocardial infarction, cardiac catheterization,
coronary artery angioplasty, or coronary artery
bypass surgery), diabetes mellitus, treated hyper-
tension, and cancer (other than nonmelanoma
skin cancer).  The computerized record of each
case was reviewed by hand to ensure that each
case fulfilled the eligibility criteria.
Control Selection
Each case was matched with up to four
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controls who did not have a myocardial
infarction by year of birth (within 2 yrs), sex,
calendar time (index date), and general practice.
In the naproxen study, because of the smaller
base population of naproxen users, up to three
controls were matched to each case.  The “index
date” for each control was the date of myocardial
infarction in their matched case.  The same
exclusion and inclusion criteria applied to cases
were applied to the controls, including the
criteria of first use of the NSAID of interest in
each study after January 1, 1999, and before the
index date; presence of at least 2 years of
recorded history in the GPRD before the index
date; and exclusion for the same diseases listed
above for the cases.
Exposure
Exposure for all study subjects was determined
for the time before the index date.  A subject was
considered exposed if they had received two or
more prescriptions for the study NSAID of
interest before the index date but after January 1,
1999.  Those with receipt of only one prescription
of the study NSAID before their index date
composed the reference group.  This reference
group was based on the randomized studies1–3
that provided evidence that receipt of only one
prescription does not increase the risk of
myocardial infarction.
Analysis
We examined the effect of each NSAID of
interest in a separate study (one in each of the
five study populations of people who had at least
one prescription for the NSAID of interest).  We
used conditional logistic regression to estimate
odds ratios and 95% confidence intervals for
various levels of exposure (2–4, 5–9, 10–19, and
≥ 20 prescriptions) of the primary NSAID of
interest in each study compared with a single
prescription as the reference level of exposure.
We controlled each of the analyses for smoking
(never, current, past, unknown), body mass
index ([BMI] < 24 kg/m2, 24–28 kg/m2, > 28
kg/m2, unknown), history of rheumatoid
arthritis, history of hyperlipidemia, and use of
the other study NSAIDs and aspirin before the
index date.  Exposure to the other study NSAIDs
(i.e., those other than the NSAID of primary
interest in each study) and aspirin was defined as
10 or more recorded prescriptions at any time
before the index date for each drug separately
(with < 10 prescriptions, including none, as the
reference level).
Duration of use of the NSAID of primary
interest in each study was calculated as the time
from the date of the first prescription to 1 month
after the date of the last prescription.  (In the
United Kingdom, one prescription is usually
equivalent to a 30-day supply.)  Cumulative dose
was calculated as the sum over all prescriptions
of the product of the number of pills in a
prescription and the strength of the pills in that
prescription.  We estimated the correlation
between number of prescriptions and duration of
use and the correlation between number of
prescriptions and cumulative dose by using a
nonparametric measure (Spearman correlation
coefficient).
Statistical calculations were performed by
using SAS Release 9.1 software (SAS Institute
Inc., Cary, NC).
Results
We identified more than 600,000 patients in
the GPRD who had received a first prescription
for at least one of the five study drugs some time
after January 1, 1999.  Characteristics of the
cases and controls are given in Table 1.  The
mean duration of recorded history before the
index date for cases and controls combined was
11.2 years in the rofecoxib study, 11.0 years in
the celecoxib study, 9.1 years in the ibuprofen
study, 10.2 years in the naproxen study, and 9.8
years in the diclofenac study.  The duration of
recorded history was similar for cases and
controls within each study.
Rofecoxib
Among subjects who received one or more
prescriptions for rofecoxib, we identified 112
patients with myocardial infarction and 421
matched controls who had received rofecoxib for
the first time after January 1, 1999, and before
their index date (Table 1).  About one third of
cases (and controls) were age 59 years or younger,
one third were 60–69 years, and one third were
70 years or older.  Nearly two thirds were male.  
The RR estimate comparing cases and controls
for all rofecoxib users who were prescribed at
least two prescriptions (range 2–54 prescriptions)
compared with those who were prescribed only
one prescription was 1.5 (95% CI 1.0–2.4).  The
adjusted RR estimates, according to number of
prescriptions received are provided in Table 2.
The RR estimate for those prescribed 2–4 and
5–9 prescriptions compared with one prescription
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were 1.5 and 1.0, respectively.  For people who
were prescribed 10–19 prescriptions (14 cases, 40
controls), the RR estimate was 1.7 (95% CI
0.8–3.8) and for those prescribed 20 or more
prescriptions (9 cases, 16 controls) it was 3.1
(95% CI 1.1–8.9).  A test for trend by exposure
category provided evidence that an increasing
number of prescriptions is associated with an
increasing risk of myocardial infarction (p=0.07).
Of note, five of the nine patients who received 20
or more prescriptions for rofecoxib received their
last prescription 4 or more months before their
myocardial infarction.
Duration of rofecoxib use (i.e., the time from
the date of the first prescription to a date 1
month after the last prescription before the index
date) correlated with the number of rofecoxib
prescriptions (r=0.97, p<0.0001).  For those with
a single prescription, the duration of use was 1
month by definition.  For those with 2–4
prescriptions, the median duration was 3.6
months (interquartile range [IQR] 2.3–6.2 mo);
for 5–9 prescriptions, 9.4 months (IQR 7.2–13.3
mo); for 10–19 prescriptions, 21.1 months (IQR
14.6–27.0 mo); and for 20 or more prescriptions,
34.7 months (IQR 29.8–41.3 mo).
Cumulative dose also correlated with the
number of rofecoxib prescriptions (r=0.89,
p<0.0001).  For those with a single prescription,
the median cumulative dose was 350 mg (IQR
350–700 mg); for 2–4 prescriptions, 1400 mg
(IQR 1050–2100 mg); for 5–9 prescriptions,
4550 mg (IQR 2625–5600 mg); for 10–19
prescriptions, 9638 mg (IQR 7700–14,000 mg);
and for 20 or more prescriptions, 15,525 mg
(IQR 12,250–24,150 mg).
A higher proportion of cases than controls had
a history of rheumatoid arthritis, and cases were
more likely than controls to be current smokers
(Table 1).  The RR for a history of rheumatoid
arthritis (adjusted for the number of rofecoxib
prescriptions, BMI, smoking, hyperlipidemia, and
exposure to the other NSAIDs and aspirin) was
2.7 (95% CI 1.0–7.1).  The RR for current
smoking (adjusted for the number of rofecoxib
prescriptions, BMI, hyperlipidemia, rheumatoid
arthritis, and exposure to the other NSAIDs and
aspirin), with never smoking as the reference,
was 3.7 (95% CI 2.0–6.7).
Celecoxib
Among subjects who received one or more
prescriptions for celecoxib, we identified 109
patients with myocardial infarction and 423
matched controls who had received celecoxib for
the first time after January 1, 1999, and before
their index date (Table 1).  Case patients in the
celecoxib study tended to be older than those in
the rofecoxib study, and more than half were female.
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Table 1.  Characteristics of Case Patients and Control
Subjects by Drug Study
No. (%) of Patients
Cases Controls
Rofecoxib 112 421
Age (yrs)
≤ 59 32 (28.6) 124 (29.5)
60–69 38 (33.9) 141 (33.5)
≥ 70 42 (37.5) 156 (37.1)
Sex
Female 42 (37.5) 164 (39.0)
Male 70 (62.5) 257 (61.1)
Current smoker 41 (36.6) 92 (21.9)
Rheumatoid arthritis 10 (8.9) 14 (3.3)
Celecoxib 109 423
Age (yrs)
≤ 59 28 (25.7) 109 (25.8)
60–69 35 (32.1) 140 (33.1)
≥ 70 46 (42.2) 174 (41.1)
Sex
Female 56 (51.4) 218 (51.4)
Male 53 (48.6) 205 (48.5)
Current smoker 51 (46.8) 86 (20.3)
Rheumatoid arthritis 12 (11.0) 23 (5.4)
Ibuprofen 303 1205
Age (yrs)
≤ 59 135 (44.6) 538 (44.6)
60–69 93 (30.7) 373 (31.0)
≥ 70 75 (24.8) 294 (24.4)
Sex
Female 82 (27.1) 328 (27.2)
Male 221 (72.9) 877 (72.8)
Current smoker 130 (42.9) 261 (21.7)
Rheumatoid arthritis 7 (2.3) 9 (0.8)
Naproxen 100 287
Age (yrs)
≤ 59 57 (57.0) 168 (58.5)
60–69 25 (25.0) 74 (25.8)
≥ 70 18 (18.0) 45 (15.7)
Sex
Female 33 (33.0) 94 (32.8)
Male 67 (67.0) 193 (67.3)
Current smoker 47 (47.0) 70 (24.4)
Rheumatoid arthritis 6 (6.0) 5 (1.7)
Diclofenac 235 929
Age (yrs)
≤ 59 98 (41.7) 397 (42.7)
60-69 74 (31.5) 299 (32.2)
≥ 70 63 (26.8) 233 (25.1)
Sex
Female 62 (26.4) 243 (26.2)
Male 173 (73.6) 686 (73.8)
Current smoker 94 (40.0) 234 (25.2)
Rheumatoid arthritis 12 (5.1) 11 (1.2)
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The RR estimate comparing cases and controls
for all celecoxib users combined who were
prescribed at least two prescriptions (range 2–51
prescriptions) compared with those who were
prescribed only one prescription was similar to
that obtained with rofecoxib, 1.4 (95% CI
0.9–2.1).  The RR estimates according to number
of prescriptions received are shown in Table 3.  A
test for trend by category provided evidence for
the hypothesis that the risk of myocardial
infarction increases with an increasing number of
celecoxib prescriptions (p=0.08).
Duration of use correlated with the number of
celecoxib prescriptions (r=0.96, p<0.0001).  In
the highest exposure category (≥ 20 prescriptions),
the median duration of use was 31.2 months
(IQR 27.4–38.1 mo).
Cumulative dose also correlated with the
number of celecoxib prescriptions (r=0.92,
p<0.0001).  In the highest exposure category, the
median cumulative dose was 228,000 mg (IQR
162,000–240,000 mg).
Case patients were twice as likely to have
rheumatoid arthritis compared with controls, and
they were more than twice as likely to be current
smokers (Table 1).  The RR for a history of
rheumatoid arthritis (adjusted for the number of
celecoxib prescriptions, BMI, smoking,
hyperlipidemia, and exposure to the other
NSAIDs and aspirin) was 1.7 (95% CI 0.7–3.9).
The RR for current smoking (adjusted for the
number of celecoxib prescriptions, BMI, hyper-
lipidemia, rheumatoid arthritis, and exposure to
the other NSAIDs and aspirin), with never
smoking as the reference, was 6.7 (95% CI
3.5–12.6).
Ibuprofen
Among ibuprofen users who received one or
more prescriptions, we identified 303 patients
with myocardial infarction and 1205 controls
who received ibuprofen for the first time after
January 1, 1999, and before their index date
(Table 1).  About 45% were younger than age 59
years, 30% were age 60–69 years, and 25% were
70 years or older.  Almost three quarters of the
case patients were male.
The RR estimate comparing cases and controls
for all ibuprofen users who were prescribed at
least two prescriptions (range 2–51 prescriptions)
compared with those who were prescribed only
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Table 2.  Distribution of Number of Prescriptions of Rofecoxib for Cases and Controls
No. of No. of
No. of Cases Controls Relative Risk
Prescriptions (n=112) (n=421) Estimatea 95% CI
1 43 202 1.0 Reference
2–4 32 113 1.5 0.9–2.6
5–9 14 50 1.0 0.4–2.1
10–19 14 40 1.7 0.8–3.8
≥ 20 9 16 3.1 1.1–8.9
CI = confidence interval.
aAdjusted for body mass index, smoking, rheumatoid arthritis, hyperlipidemia, and use of other
NSAIDs (≥ 10 vs < 10 prescriptions, separately for celecoxib, ibuprofen, naproxen, diclofenac, and
aspirin).
Table 3.  Distribution of Number of Prescriptions of Celecoxib for Cases and Controls
No. of No. of
No. of Cases Controls Relative Risk
Prescriptions (n=109) (n=423) Estimatea 95% CI
1 47 216 1.0 Reference
2–4 31 115 1.3 0.7–2.4
5–9 16 46 1.5 0.8–3.2
10–19 10 34 1.8 0.7–4.3
≥ 20 5 12 1.8 0.5–6.0
CI = confidence interval.
aAdjusted for body mass index, smoking, rheumatoid arthritis, hyperlipidemia, and use of other
NSAIDs (≥ 10 vs < 10 prescriptions, separately for rofecoxib, ibuprofen, naproxen, diclofenac, and
aspirin).
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one prescription was 1.2 (95% CI 0.9–1.6).  The
adjusted RR estimates according to number of
prescriptions received are shown in Table 4.
There was no evidence of a trend by category in
the relation between the risk of myocardial
infarction and the number of prescriptions
received (p=0.6).
Duration of use (r=0.98, p<0.0001) and
cumulative dose (r=0.72, p<0.0001) both
correlated with the number of prescriptions.  The
highest exposure category (≥ 20 prescriptions)
corresponded to a median duration of use of 35.2
months (IQR 28.0–49.1 mo) and a median
cumulative dose of 780,000 mg (IQR 739,200–
1,200,000 mg).
The proportion of cases with rheumatoid
arthritis was again higher than the proportion of
controls, but these proportions were each only
approximately one fifth the respective propor-
tions of cases and controls with rheumatoid
arthritis in the rofecoxib and celecoxib studies.
As in the other studies, cases were much more
likely than controls to be current smokers (Table
1).  The RR for a history of rheumatoid arthritis
(adjusted for the number of ibuprofen
prescriptions, BMI, smoking, hyperlipidemia, and
exposure to the other NSAIDs and aspirin) was
4.8 (95% CI 1.5–15.0).  The RR for current
smoking (adjusted for the number of ibuprofen
prescriptions, BMI, hyperlipidemia, rheumatoid
arthritis, and exposure to the other NSAIDs and
aspirin), with never smoking as the reference,
was 3.7 (95% CI 2.7–5.2).
Naproxen
Among subjects who received one or more
prescriptions for naproxen, we identified 100
case patients and 287 controls who received
naproxen for the first time after January 1, 1999,
and before their index date (Table 1).  More than
half the cases and controls were younger than 59
years and less than one fifth were age 70 years or
older. Two thirds of the case patients were male.
The RR estimate comparing cases and controls
for all naproxen users who were given at least
two prescriptions (range 2–78 prescriptions)
compared with those who were given only one
prescription was 1.4 (95% CI 0.8–2.3).  The
adjusted RR estimates by number of prescriptions
are presented in Table 5.  No evidence of a trend
by category was noted in the relation between the
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Table 4.  Distribution of Number of Prescriptions of Ibuprofen for Cases and Controls
No. of No. of
No. of Cases Controls Relative Risk
Prescriptions (n=303) (n=1205) Estimatea 95% CI
1 201 845 1.0 Reference
2–4 78 279 1.2 0.8–1.6
5–9 14 49 1.2 0.6–2.3
10–19 8 23 1.0 0.4–2.4
≥ 20 2 9 0.9 0.2–4.2
CI = confidence interval.
aAdjusted for body mass index, smoking, rheumatoid arthritis, hyperlipidemia, and use of other
NSAIDs (≥ 10 vs < 10 prescriptions, separately for rofecoxib, celecoxib, naproxen, diclofenac, and
aspirin).
Table 5.  Distribution of Number of Prescriptions of Naproxen for Cases and Controls
No. of No. of
No. of Cases Controls Relative Risk
Prescriptions (n=100) (n=287) Estimatea 95% CI
1 56 185 1.0 Reference
2–4 37 66 2.2 1.2–4.0
5–9 1 24 0.2 0.02–1.3
10–19 3 6 1.9 0.4–10.3
≥ 20 3 6 2.5 0.5–13.8
CI = confidence interval.
aAdjusted for body mass index, smoking, rheumatoid arthritis, hyperlipidemia, and use of other
NSAIDs (≥ 10 vs < 10 prescriptions, separately for rofecoxib, celecoxib, ibuprofen, diclofenac, and
aspirin).
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risk of myocardial infarction and increasing
numbers of naproxen prescriptions (p=0.4).
Rheumatoid arthritis was again more common
among the cases than the controls, with the
respective proportions intermediate between
those in the COX-2 inhibitor studies and those in
the ibuprofen study. As in all the other studies,
the proportion of current smokers was
substantially higher among cases than among
controls (Table 1).  The RR for a history of
rheumatoid arthritis (adjusted for the number of
naproxen prescriptions, BMI, smoking,
hyperlipidemia, and exposure to the other
NSAIDs and aspirin) was 3.3 (95% CI 0.7–15.7).
The RR for current smoking (adjusted for the
number of naproxen prescriptions, BMI, hyper-
lipidemia, rheumatoid arthritis, and exposure to
the other NSAIDs and aspirin), with never smoking
as the reference, was 3.9 (95% CI 2.0–7.6).
Diclofenac
Among subjects who received one or more
prescriptions for diclofenac, we identified 235
case patients and 929 matched controls who
received diclofenac for the first time after January
1, 1999, and before their index date (Table 1).
About 40% of cases (and controls) were age 59
years or younger, one third were 60–69 years,
and one quarter were 70 years or older.  Nearly
three quarters were male.
The RR estimate comparing cases and controls
for all diclofenac users who were prescribed at
least two prescriptions (range 2–63 prescriptions)
compared with those who were prescribed only
one prescription was 1.0 (95% CI 0.8–1.4).  The
adjusted RR estimates according to number of
prescriptions received are provided in Table 6.
The RR estimate for those prescribed 2–4 and
5–9 prescriptions compared with one prescription
were 0.7 and 1.2, respectively.  For people who
were prescribed 10–19 prescriptions (17 cases, 26
controls), the RR estimate was 2.5 (95% CI
1.2–5.0) and for those prescribed 20 or more
prescriptions (14 cases, 18 controls) it was 2.6
(95% CI 1.2–5.9).  A test for trend by category
provided evidence that an increasing number of
prescriptions is associated with an increasing risk
of myocardial infarction (p=0.02).
Duration of use correlated with the number of
diclofenac prescriptions (r=0.97, p<0.0001).  For
those with 10–19 prescriptions, the median
duration of use was 28.4 months (IQR 16.2–35.9
mo); for 20 or more prescriptions, it was 38.8
months (IQR 29.0–55.5 mo).
Cumulative dose also correlated with the
number of diclofenac prescriptions (r=0.81,
p<0.0001).  For those with 10–19 prescriptions,
the median cumulative dose was 52,500 mg (IQR
42,000–60,900 mg); and for those with 20 or
more prescriptions, it was 114,800 mg (IQR
88,350–150,500 mg).
The proportions of cases and controls with a
history of rheumatoid arthritis were similar to
those in the naproxen study, and cases were again
much more likely than controls to be current
smokers (Table 1).  The RR for a history of
rheumatoid arthritis (adjusted for the number of
diclofenac prescriptions, BMI, smoking,
hyperlipidemia, and exposure to the other
NSAIDs and aspirin) was 2.6 (95% CI 0.9–7.1).
The RR for current smoking (adjusted for the
number of diclofenac prescriptions, BMI,
hyperlipidemia, rheumatoid arthritis, and
exposure to the other NSAIDs and aspirin), with
never smoking as the reference, was 2.3 (95% CI
1.6–3.4).
Discussion
Three randomized clinical trials have provided
virtually irrefutable evidence that prolonged use
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Table 6.  Distribution of Number of Prescriptions of Diclofenac for Cases and Controls
No. of No. of
No. of Cases Controls Relative Risk
Prescriptions (n=235) (n=929) Estimatea 95% CI
1 141 571 1.0 Reference
2–4 46 254 0.7 0.5–1.0
5–9 17 60 1.2 0.6–2.2
10–19 17 26 2.5 1.2–5.0
≥ 20 14 18 2.6 1.2–5.9
CI = confidence interval.
aAdjusted for body mass index, smoking, rheumatoid arthritis, hyperlipidemia, and use of other
NSAIDs (≥ 10 vs < 10 prescriptions, separately for rofecoxib, celecoxib, ibuprofen, naproxen, and
aspirin).
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of the COX-2 inhibitors rofecoxib and celecoxib
increases the risk for acute myocardial infarction
specifically, and cardiovascular disorders in
general, by as much as 2-fold or more.1–3
Randomized clinical trials regularly yield the
most reliable information on the safety of drugs,
particularly when adverse effects are reasonably
common and the trials are both large and
extended in time.  Trials are particularly useful in
people who are at high risk for the adverse effect
of interest, since observational (nonrandomized)
studies often contain important biases that
cannot be precisely measured and controlled and
thus often affect and distort their results.10
Randomized trials are designed to minimize such
biases among the comparison groups.  Large
controlled trials are particularly salutary in
evaluating the relation of NSAID use and the risk
of myocardial infarction and other cardiovascular
events.
The first reported randomized study, Vioxx
Gastrointestinal Outcomes Research (VIGOR),
compared patients who received rofecoxib 50
mg/day with those receiving naproxen 500 mg
twice/day.1 The risk of myocardial infarction was
reported to be 0.1% (4/4029) in naproxen
recipients and 0.4% (16/4047) in recipients of
rofecoxib.  Astonishingly, the authors (and others
responsible for the publication) chose to provide
only the RR for myocardial infarction of 0.2 (95%
CI 0.1–0.7) for naproxen compared with
rofecoxib.  The authors concluded that their
results were “consistent with the theory that
naproxen has a coronary protective effect and
highlight the fact that rofecoxib does not provide
this type of protection.”  There is no mention of
the possibility that rofecoxib might increase the
risk for myocardial infarction.  Nor is there
information on time of exposure before the date
of myocardial infarction.
The Adenomatous Polyp Prevention on Vioxx
(APPROVE) study compared patients who
received rofecoxib 25 mg (half the dose used in
the VIGOR study) with those who received
placebo, with follow-up for as long as 36
months.3 The RR comparing rofecoxib users
with placebo users from the start of the trial up
to 18 months was reported to be 1.18.  By
contrast, the RR for months 19–36 was reported
to be 4.45.  Had this study been designed with a
follow-up period of 18 months or less, no
difference between rofecoxib and placebo would
have been found.
In the Adenoma Prevention with Celecoxib
(APC) study, which compared two doses of
celecoxib and placebo with 36 months of follow-
up, the increased risk of serious cardiac events
was 2.3 for patients receiving celecoxib 200 mg
twice/day and 3.4 for patients receiving 400 mg
twice/day compared with placebo.2 The effect in
celecoxib users appeared to start at about 10–12
months after treatment began, and the risk was
higher in those who received the higher dose.
Thus, there is convincing evidence from these
trials that the increased cardiovascular risk
attributable to the two COX-2 preparations is
highly correlated with the cumulative dose
received.
Our study provides additional persuasive
evidence on this issue, since the findings are
compatible with those of randomized studies.  As
in the trials discussed above,1–3 extensive use
appears to be a critical determinant of the effect.
In our study, we emphasized the extent of use for
each study drug of interest rather than the
currency of use.  By focusing on a particular
NSAID of interest in each of our separate studies,
we avoided the problem with other investigations
that categorized patients as having been exposed
to the particular NSAID that was prescribed
closest in time to the index date when they may
have received more extended use of another
NSAID previously (and the previously used
NSAID may have had more influence on their
risk for myocardial infarction).  This likely
explains at least in part why our results are more
similar to those of the clinical trials1–3 than are
other observational studies,8 which yielded
generally null effects.  The previous observational
studies on NSAIDs and myocardial infarction,
with a few exceptions,11, 12 identified subjects
who were currently exposed to an NSAID and
compared current use of each drug with
noncurrent exposure as the referent.  We found
an increased risk of myocardial infarction in
rofecoxib users who received 20 or more
prescriptions, a finding that is concordant with
the results of the APPROVE study,3 in which the
increased risk for myocardial infarction among
those receiving rofecoxib as compared with
placebo became manifest after approximately 18
months of treatment.
An important additional new finding from our
study is that prolonged use of diclofenac, a
commonly used NSAID, also increases the risk
for acute myocardial infarction more than 2-fold
in the highest exposure categories.  The public
health implication of this finding is substantial
since we estimate, based on the GPRD, that more
than 15 million people in the United Kingdom
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have been prescribed diclofenac, sometimes on a
continuous basis, in the past 20 years.  Approxi-
mately 11% of these have 10 or more prescrip-
tions recorded.  Note that diclofenac has the
highest COX-2 selectivity among the traditional
NSAIDs.13
A majority of studies8 included people with
important clinical risk factors for myocardial
infarction (e.g., angina and diabetes).  In all
instances, as expected, the cases compared with
controls had a substantially higher proportion of
people with these prior illnesses.  There is an
assumption in the analysis that the severity of
these illnesses (all treated as dichotomous
variables) is the same in cases and controls,
which is surely incorrect since the cases had a
myocardial infarction and the controls did not.
The net effect of these considerations is that they
may distort the results to a measurable amount.
Because most published studies encompass
thousands of cases and controls, such biases—if
present—will tend to result in small but
“statistically significant” differences between
cases and controls, which are sometimes inferred
to be causal when, in fact, they are due to small
biases relative to cases and controls.10 In our
study, we excluded cases and controls with
preexisting risk factors for myocardial infarction.
Failure to remove these subjects from an
observational study may well bias any true drug
effect that is present.
Conclusion
The extent of NSAID use appears to be the
critical determinant in the relation of most
marketed NSAIDs to myocardial infarction.  The
findings of this study are consistent with the
results of the clinical trials with respect to the
effect of prolonged use of rofecoxib and celecoxib
and the risk of myocardial infarction.  In this
study, this increased risk also appeared to be
present in diclofenac users but not in users of
ibuprofen or naproxen.
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Risk of Impaired Renal Function After Colonoscopy:
A Cohort Study in Patients Receiving Either Oral Sodium
Phosphate or Polyethylene Glycol
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OBJECTIVES: We aimed to evaluate frequency, predictors, and monitoring of renal dysfunction related to the use
of oral sodium phosphates for colonoscopy in clinical practice.
METHODS: Cohort study using clinical records and electronic patient information from the Henry Ford Health
System, Detroit, MI. We identified patients undergoing colonoscopy using sodium phosphate or
polyethylene glycol (PEG), and estimated the risk of renal impairment associated with bowel
preparation and other risk factors.
RESULTS: Out of 7,897 patients, 6,833 had used sodium phosphate; 1,617 patients had renal dysfunction
within 12 months prior to colonoscopy and 3,928 patients had no creatinine measurement within
12 months prior to or 6 months postcolonoscopy. Among the remaining 2,352 patients, 88 had
incident renal dysfunction (glomerular filtration rate [GFR] <60 mL/min) after colonoscopy. The
relative risk (RR) estimate for renal dysfunction comparing sodium phosphate with PEG was 1.13
(95% CI 0.58–2.23) without adjustment, and 1.14 (95% CI 0.55–2.39) after multivariate
adjustment. Significant univariate risk factors were age ≥65 yr, African-American race, low baseline
GFR, hypertension, and use of angiotensin-converting enzyme inhibitors (ACE inhbitors),
angiotensin-renin blockers, or thiazide diuretics.
CONCLUSIONS: In patients without preexisting renal disease, the risk of renal impairment after colonoscopy appears
to be similar between sodium phosphate and PEG users. Sodium phosphate use in patients with
preexisting renal disease is not recommended, but common in clinical practice. Sodium phosphate
should not be used in patients with preexisting serious renal disease, adequate hydration should be
assured in all patients, and renal function should be monitored before and after colonoscopy in
those at risk of renal dysfunction.
(Am J Gastroenterol 2007;102:2655–2663)
INTRODUCTION
Reports of renal failure after colonoscopy using sodium
phosphate-containing bowel cleansing preparations have
raised concern about their safety (1–6). The labeling of oral
sodium phosphates has therefore been repeatedly updated,
and now includes a contraindication for its use in serious re-
nal disease and congestive heart failure, and recommends its
cautious use in patients with impaired renal function, heart
disease, ascites, dehydration, and electrolyte disturbances, as
well as in elderly patients. In addition, the need for adequate
hydration is emphasized and there is a warning not to exceed
the recommended dose.
These warnings are also supported by previous studies
showing that oral sodium phosphates may cause intravascu-
lar volume depletion and may increase the calcium phosphate
product, providing a plausible pathophysiological hypothesis
for the occurrence of nephrocalcinosis and subsequent renal
impairment (7). Indeed, nephrocalcinosis has been described
in cases where renal histology was available, although only
one reported case has a baseline histology before colonoscopy
that provides additional evidence for a causal relationship (6).
In clinical trials, no cases of renal failure after use of oral
sodium phosphates were reported. However, the population
in these trials may not represent patients who receive sodium
phosphates in clinical practice where risk factors for the de-
velopment of renal complications may be more prevalent,
and they included only a limited number of patients, pre-
venting the detection of very rare adverse events. So far, no
studies have evaluated the incidence and relative risk of renal
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complications after use of oral sodium phosphates as com-
pared to other preparations in clinical practice.
We conducted a formal epidemiological study in recipients
of oral bowel preparation agents containing either sodium
phosphate or polyethylene glycol (PEG) that aimed to evalu-
ate the risk of incident renal complications after colonoscopy
in clinical practice and its association with the used bowel
preparation.
METHODS
Data Source
Information for this study was derived from the procedure
database of the Gastroenterology Department at Henry Ford
Health System (HFHS) Detroit campus, Detroit, MI, and the
administrative databases within HFHS. The Gastroenterol-
ogy database contains detailed information on colonoscopies
including date, bowel cleansing preparation, and adequacy of
preparation, as well as the medical record number as a unique
patient identifier that allows linkage to the HFHS adminis-
trative databases and electronic medical record. The HFHS
database contains information on medical care encounters,
diagnoses, procedures, outpatient drug prescriptions, labo-
ratory results, and patient demographics. Additionally, for
patients enrolled in Health Alliance Plan (HAP), an HFHS
owned and operated health maintenance organization, exter-
nal claims for care are also available. Drug prescriptions are
coded using the National Drug Code (NDC) provided by the
U.S. Food and Drug Administration (FDA). All diagnoses are
coded using the ICD-9 coding system; procedures are coded
using the CPT4 coding system. All events are noted with the
date on which the initial service was delivered. We also had
access to original medical records and laboratory results of
all patients enrolled in HAP.
The study was approved by the HFHS Human Rights Com-
mittee with a waiver of authorization.
Study Population
The study was based within the population of all patients who
had a colonoscopy at the HFHS Detroit center’s gastroenterol-
ogy clinic between November 1, 1999 and October 31, 2005,
Table 1. Criteria for the Identification of Preexisting Renal
Diseases
Outcome Criteria
Undergoing dialysis ICD-9 diagnosis: V45.1,
V56–V56.8
HFHS billing codes for dialysis
External claims for dialysis
History of kidney transplant ICD-9 diagnosis: V42.0
Acute renal failure ICD-9 diagnosis: 584.5–584.9
Chronic renal failure ICD-9 diagnosis: 585
Unspecified renal failure ICD-9 diagnosis: 586
Functional renal impairment GFR <60 mL/min
stage 3 or greater
who received oral bowel cleansing preparations containing
either sodium phosphate (Phospho-soda, C.B. Fleet Com-
pany, Inc., Lynchburg, VA) or PEG (COLYTE, Schwarz
Pharma, Inc., Milwaukee, WI), and were enrolled in the HAP
from 12 months prior to 6 months postcolonoscopy. From
this population, we excluded all patients with preexisting re-
nal disease within 12 months prior to colonoscopy according
to predefined criteria (Table 1). Subsequently, we obtained
all creatinine values determined within 12 months prior to
and 6 months postcolonoscopy for the remaining patients,
and calculated glomerular filtration rate (GFR) estimates ac-
cording to the modification of diet in renal disease (MDRD)
study formula (8). We then excluded additional patients with
a GFR <60 mL/min within 12 months prior to colonoscopy,
and those who did not have a creatinine determination within
12 months prior to and 6 months postcolonoscopy. This selec-
tion process assured that our final study population included
only patients with sufficient information for identification
and differential diagnostic evaluation of renal impairment in
relation to colonoscopy.
We also extracted additional electronic information on de-
mographics, preexisting concomitant drug use, and comor-
bidities for all patients in the study population (Table 2). Drug
prescriptions within 3 months prior to colonoscopy were iden-
tified as a proxy for current drug use. For the identification
of comorbidities, we searched for related diagnostic codes or
procedures within 12 months prior to colonoscopy. In addi-
tion to specific conditions of interest, the diagnostic coding
was used to calculate the Charlson comorbidity index. Origi-
nally developed to assess survival probability based on inpa-
tient medical record review, this methodology is also useful
with administrative databases as a means of measuring un-
derlying burden of illness (9, 10).
Definition, Identification, and Validation of Cases
From the study population, we identified all patients where
the first creatinine determination within 6 months after
colonoscopy corresponded to a GFR <60 mL/min and
showed a decrease of at least 10 mL/min versus the last value
before colonoscopy. The focus on the first creatinine value af-
ter colonoscopy was based on the assumption that renal dam-
age in relation to colonoscopy would manifest soon there-
after. We also searched for patients with at least a twofold
increase in creatinine, regardless of whether the GFR after
colonoscopy was <60 mL/min. Two physicians, with exper-
tise in causality assessment of suspected adverse drug reac-
tions (Stefan Russmann and Judith K. Jones), then reviewed
the original clinical records of these patients, while being
blinded with regard to the bowel preparation agent used (this
information is not part of the clinical records but kept in the
Gastroenterology database, which was later incorporated into
the main dataset for the final analysis). Patients with an iden-
tifiable, likely cause of renal impairment other than bowel
preparations were subsequently excluded. The remaining pa-
tients were considered as “idiopathic” cases of renal im-
pairment, and therefore, to have at least a possible causal
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Table 2. Baseline Characteristics of the Study Population
Sodium Phosphate Polyethylene Glycol
Characteristics Users (N = 2,083) Users (N = 269)
Sex
Female 1,158 (55.6%) 137 (50.9%)
Male 925 (44.4%) 132 (49.1%)
Age (yr)
<65 1,284 (61.6%) 131 (48.7%)
≥65 799 (38.4%) 138 (51.3%)
Race
African American 1,454 (69.8%) 183 (68.0%)
White 548 (26.3%) 82 (30.5%)
Others 81 (3.9%) 4 (1.5%)
Colonoscopy date
Nov 1, 1999 to Oct 31, 2000 224 (10.8%) 56 (20.8%)
Nov 1, 2000 to Oct 31, 2001 285 (13.7%) 27 (10.0%)
Nov 1, 2001 to Oct 31, 2002 350 (16.8%) 34 (12.6%)
Nov 1, 2002 to Oct 31, 2003 477 (22.9%) 36 (13.4%)
Nov 1, 2003 to Oct 31, 2004 420 (20.2%) 34 (12.6%)
Nov 1, 2004 to Oct 31, 2005 327 (15.7%) 82 (30.5%)
Inpatient colonoscopy 199 (9.6%) 97 (36.1%)
GI bleeding 30 days prior to colonoscopy 241 (11.6%) 77 (28.6%)
Hospitalization 12 months prior to colonoscopy 435 (20.9%) 126 (46.8%)
Baseline GFR ≥60 and <90 mL/min 1,023 (49.1%) 119 (44.2%)
Baseline comorbidities∗
Hypertension 1,277 (61.3%) 179 (66.5%)
Diabetes mellitus 504 (24.2%) 68 (25.3%)
Congestive heart failure 74 (3.6%) 40 (14.9%)
Liver cirrhosis 34 (1.6%) 8 (3.0%)
Charlson comorbidity index
0 1,007 (48.3%) 94 (34.9%)
1–2 876 (42.1%) 128 (47.6%)
≥3 200 (9.6%) 47 (17.5%)
Current drug therapy†
Angiotensin-converting enzyme inhibitors 411 (19.7%) 52 (19.3%)
Angiotensin-renin blockers 87 (4.2%) 20 (7.4%)
Loop diuretics 99 (4.8%) 27 (10.0%)
Thiazide diuretics 415 (19.9%) 42 (15.6%)
Beta blockers 397 (19.1%) 75 (27.9%)
Calcium channel blockers 382 (18.3%) 50 (18.6%)
Nonsteroidal antiinflammatory drugs 449 (21.6%) 46 (17.1%)
∗Diagnoses within 12 months prior to colonoscopy.
†Prescriptions within 3 months prior to colonoscopy.
relationship to colonoscopy with bowel preparation. In ad-
dition, we also searched for any diagnoses indicating renal
dysfunction (Table 1) after colonoscopy in the base popula-
tion, in order to assure that there were no patients with clini-
cally diagnosed renal dysfunction, but no available creatinine
value.
Data Analysis
We calculated the incidence of renal impairment during the 6-
month period after colonoscopy, and estimated the unadjusted
relative risk (RR) in patients receiving oral sodium phosphate
versus PEG as the incidence ratio for these two groups. We
used logistic regression in order to calculate odds ratios (OR)
as an estimate of RR, and to control for the possible effects
of patient demographics, drug use, and comorbidities at the
time of colonoscopy. In addition, we used propensity score
methodology as an alternative way to control for confound-
ing, i.e., we generated a logistic regression model that calcu-
lated a patient’s propensity to receive sodium phosphate or
PEG based on patient demographics, current drug use, and
medical history. Subsequently, we used this propensity score
as a continuous covariate in a logistic regression model that
measured the association between bowel preparation and re-
nal impairment, and also as the basis for stratification of the
study population into quintiles for stratified analysis accord-
ing to the Mantel-Haenszel method (11, 12).
Data were analyzed using STATA 8.2 for MacOS X
(STATA Corp LP, College Station, TX) and SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL).
RESULTS
We identified a base population of 7,897 patients with con-
tinuous health plan enrollment that underwent colonoscopy
and used either oral sodium phosphate or PEG for prepa-
ration. Within 12 months prior to colonoscopy, 595 out of
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BASE POPULATION
Patients undergoing colonoscopy with polyethylen-
glycol or sodium phosphate between 1 Nov 1999 
and 31 Oct 2005, and enrollment in Health Aliance 
Plan 12 months prior to and 6 months postcolonoscopy.
Exclusions
Patients with renal dysfunction within 12 
months prior to colonoscopy (dialysis, renal  
failure diagnosis, or GFR<60 mL/min).
 
Patients without creatinine determination 
within 12 months prior to or 6 months
STUDY POPULATION
Patients without preexisting renal dysfunction, 
and with available medical records and creatinine 
determination within 12 months prior to and 6 
months postcolonoscopy. 
CASES
Patients with incident idiopathic renal 
impairment after colonoscopy.
Case identification and validation
GFR <60 mL/min and GFR delta >10 mL/min, 
and/or at least twofold increase in creatinine 
within 6 months postcolonoscopy. 
No cause for renal impairment identifiable in 
medical records.
Polyethylen-
glycol
1,064
595
200
269
9
Sodium 
phosphate
6,833
1,022
3,728
2,083
79
Total
7,897
1,617
3,928
2,352
88
postcolonoscopy. 
Figure 1. Identification of study population and cases.
1,064 PEG users (55.9%) and 1,022 out of 6,833 sodium
phosphate users (15.0%) had renal dysfunction. Of the re-
maining 469 PEG and 5,811 sodium phosphate users, 43
(9.2%) and 1,025 (17.6%), respectively, had no creatinine
determination within 12 months prior to colonoscopy, and
190 (40.5%) and 3,540 (60.9%), respectively, had no crea-
tinine determination within 6 months postcolonoscopy. Two
hundred (42.6%) and 3,728 (64.2%), respectively, had no cre-
atinine determinations within 12 months prior to or 6 months
postcolonoscopy, leading to a final study population of 2,352
patients (Fig. 1). Furthermore, we identified 1,621 patients
in the base population who had a GFR <90 mL/min within
12 months prior to colonoscopy, but no creatinine determi-
nation within 6 months thereafter. Of those, 1,517 patients
had used sodium phosphate, of which 174 even had a GFR
<60 mL/min.
Demographics and baseline characteristics before
colonoscopy of the study population are presented in
Table 2. Compared to the patients receiving sodium phos-
phate, those receiving PEG were on average older and had
a higher prevalence of heart failure, use of diuretics or
drugs acting on the angiotensin system, and comorbidities
according to the Charlson index. They were also more
likely to have a colonoscopy as an inpatient procedure, and
to be hospitalized for any reason during the 12 months
before colonoscopy. However, in the study population, the
proportion of patients with mild renal impairment before
colonoscopy (GFR between 60 and 90 mL/min) was similar
in PEG and sodium phosphate users (44.2 vs 49.1%). Table
2 also shows an increase in the use of PEG in 2005.
Within the study population, we identified 100 patients
that fulfilled the study’s criteria for renal impairment after
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Table 3. Reasons for Exclusion of 12 Patients With Renal Dysfunction After Colonoscopy From Study Cases Because Other Likely Causes
of Renal Dysfunction Were Identified During Review Blinded to Bowel Preparation
Likely Cause for Renal Dysfunction Category
Three months after colonoscopy: Hospital admission due to syncope. Cardiac catheter with contrast medium
application and diagnosis of aortic and mitral valve stenosis with pulmonary hypertension. Recovery of renal
function a few days after admission.
Prerenal and/or
contrast medium
Five months after colonoscopy: Pneumonia with acute decompensation of chronic heart failure. Recovery of renal
function after treatment of pneumonia and heart failure.
Prerenal
One month after colonoscopy: Hospitalization for recurrent lower gastrointestinal hemorrhage. Known alcohol abuse
was the possible additional cause of dehydration. Recovery of renal function after rehydration.
Prerenal
Three months after colonoscopy: Hospital admission with acute upper gastrointestinal bleeding and hypotension.
Recovery of renal function after rehydration.
Prerenal
Four months after colonoscopy: Hospitalization for acute pneumonia. Recovery of renal function after treatment of
pneumonia.
Prerenal
Four months after colonoscopy: Severe lower gastrointestinal hemorrhage and acute renal failure with hematuria. Prerenal
Five months after colonoscopy: Hospital admission with 6-wk history of diarrhea. Diagnosis of acute renal failure
due to hypovolemia. Recovery of renal function after rehydration.
Prerenal
Two weeks after colonoscopy: Patient found unconscious at home, and with clavicular fracture and chronic
alcoholism. Recovery of renal function after rehydration.
Prerenal
Two months after colonoscopy: Recurrent (not incident) acute nephrolithiasis. Several events of nephrolithiasis
before colonoscopy.
Postrenal
Two days after colonoscopy: Lower urinary tract obstruction and infection. Clots in urine. Cytology suggested
malignancy. Recovery of renal function after passage of urinary catheter.
Postrenal
Three months after colonoscopy and shortly after prostatectomy: Bladder neck obstruction with urinary tract
infection and irreversible acute renal failure.
Postrenal
Creatinine value of 9.5 mg/dL at discharge without indication of renal disease in medical record. “Do not correlate”
comment in laboratory file.
Laboratory error
colonoscopy. Twelve patients had other identifiable causes
for postcolonoscopy renal dysfunction and were therefore
excluded: seven had a likely prerenal cause for decreased
GFR other than isolated cardiovascular decompensation af-
ter colonoscopy, one had a likely prerenal cause plus contrast
medium application, three had a likely postrenal cause other
than incident nephrolithiasis, and in one a very high creati-
nine value was identified as a laboratory error (Table 3). The
remaining 88 patients were considered as cases of incident
idiopathic renal impairment after colonoscopy. Seventy-nine
patients had used oral sodium phosphate, and nine had used
PEG, corresponding to 3.8% and 3.3% of the exposed patients
in the study population, respectively. Of those, 50 patients had
a GFR decrease of at least 20 mL/min, and 13 had at least a
twofold increase in creatinine after colonoscopy. Looking at
the further course of GFR, 36 cases did not have additional
creatinine determinations within 6 months postcolonoscopy,
and in 31 patients, GFR returned to >60 mL/min. In 21 cases,
GFR remained <60 mL/min, and out of those, 17 had used
sodium phosphate and four had used PEG, i.e., 21.5% of the
79 cases who had used sodium phosphate versus 44.4% of
the nine cases who had used PEG.
Baseline characteristics and unadjusted RR for impaired
renal function after colonoscopy in relation to these factors
are presented in Table 4. As shown, age ≥65 yr, African-
American race, low baseline GFR, hypertension, and the
use of angiotensin converting enzyme (ACE) inhibitors,
angiotensin-renin blockers, or thiazide diuretics showed a
significant univariate association with renal impairment. In
contrast, the use of oral sodium phosphate was not associated
with renal impairment when compared with PEG.
Adjusted RR estimates are presented in Table 5. Regard-
less of whether conventional logistic regression or propensity
score methodology was used to control confounding, adjusted
RR estimates were very similar to the unadjusted RR (Table 4)
and indicated a comparable risk of renal impairment after the
use of sodium phosphate or PEG. Restriction of the analysis
to the 50 cases with a decrease in GFR of at least 20 mL/min
after colonoscopy resulted in very similar RR estimates. The
data did not provide evidence for effect modification of the
RR by decreased baseline GFR, age ≥65 yr, or use of ACE
inhibitors, angiotensin-renin blockers, or diuretics (RR af-
ter stratification over bowel preparation agent were similar
to each other and to the combined estimates). Also, adjust-
ment for differences in the latency time from colonoscopy to
creatinine determination did not alter the risk estimates.
DISCUSSION
Reports of acute renal failure after bowel preparation with
sodium phosphates have raised concern about its safety (1–
6). Nephrocalcinosis was found in renal biopsies in some
of these patients (1, 2, 4, 6), and it has been shown that oral
sodium phosphates used for bowel preparation can lead to hy-
povolaemia, hyperphosphataemia, and hypocalcaemia with
a subsequent increase in the calcium-phosphorus solubility
product (13–18). Although these findings provide a plausi-
ble mechanistic hypothesis for the development of acute and
chronic renal injury associated with sodium phosphate, the
public health implication of this safety signal is unclear. Be-
cause spontaneous reports allow no quantification of the risk,
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Table 4. Risk of Impaired Renal Function After Colonoscopy in Relation to Selected Factors
Patients With Factor Patients Without Factor
and With Impaired and With Impaired
Renal Function∗ Renal Function∗
Factors N Risk†a N Risk†b RR‡ (95% CI)
Sodium phosphate use 79 3.8% 9 3.3% 1.13 (0.58–2.23)
Female 55 4.2% 33 3.1% 1.36 (0.89–2.08)
Age ≥65 yr 60 6.4% 28 2.0% 3.23 (2.08–5.03)
African-American race 70 4.3% 18 2.5% 1.70 (1.02–2.83)
Inpatient colonoscopy 6 2.0% 82 4.0% 0.51 (0.22–1.15)
GI bleeding 30 days prior 10 3.1% 78 3.8% 0.82 (0.43–1.57)
to colonoscopy
Hospitalization 12 months prior 10 1.8% 78 4.4% 0.41 (0.21–0.79)
to colonoscopy
GFR ≥60 and <90 mL/min 74 6.5% 14 1.2% 5.60 (3.18–9.86)
Comorbidities§
Hypertension 73 5.0% 15 1.7% 2.99 (1.73–5.19)
Diabetes mellitus 25 4.4% 63 3.5% 1.23 (0.78–1.94)
Congestive heart failure 7 6.1% 81 3.6% 1.70 (0.80–3.59)
Liver cirrhosis 0 0% 88 3.8% – –
Charlson index ≥2 20 3.5% 68 3.8% 0.90 (0.55–1.47)
Current drug therapy¶
ACE inhibitors 28 6.0% 60 3.2% 1.90 (1.23–2.95)
Angiotensin-renin blockers 10 9.3% 78 3.5% 2.69 (1.43–5.05)
Loop diuretics 4 3.2% 84 3.8% 0.84 (0.31–2.26)
Thiazide diuretics 31 6.8% 57 3.0% 2.26 (1.47–3.45)
Beta blockers 17 3.6% 71 3.8% 0.95 (0.57–1.60)
Calcium channel blockers 23 5.3% 65 3.4% 1.57 (0.99–2.50)
Nonsteroidal antiinflammatories 19 3.8% 69 3.7% 1.03 (0.63–1.70)
∗GFR <60 mL/min after colonoscopy and decrease from baseline before colonoscopy >10 mL/min;
†aRisk of impaired renal function in patients with factor; †bRisk of impaired renal function in patients without factor.
‡Unadjusted relative risk ( RR) of impaired renal function after colonoscopy for presence versus absence of factor;
§Diagnoses within 12 months prior to colonoscopy;
¶Prescriptions within 3 months prior to colonoscopy.
and the risk of renal impairment has not been studied in a large
number of patients in a clinical practice setting, it is unknown
whether severe cases reported in the literature may only be
the “tip of the iceberg.” Further, sodium phosphates may also
increase the risk of chronic subclinical renal impairment in
clinical practice. On the other hand, previous clinical trials
comparing sodium phosphates with PEG in patients without
preexisting renal disease demonstrated sodium phosphate’s
equal or superior tolerability and efficacy as well as its safety
(19).
Table 5. Absolute Numbers and Unadjusted Absolute Risk of Incident Impaired Renal Function After Colonoscopy, and Adjusted Odds
Ratios Estimating the Risk of Renal Impairment Associated With Sodium Phosphate versus Polyethylene Glycol
Patients With Adjusted Odds Adjusted Odds
Impaired Renal Ratio Using Ratio Using Propensity
Function∗ Conventional Logistic Score Based Logistic
All Patients Regression† Regression‡
(N) (N) (%) (95% CI) (95% CI)
Polyethylene glycol 269 9 3.3 1.0 (ref) 1.0 (ref)
Sodium phosphate 2,083 79 3.8 1.07 (0.51–2.23) 1.14 (0.55–2.39)
∗GFR <60 mL/min after colonoscopy and decrease from baseline before colonoscopy >10 mL/min;
†Adjusted odds ratios (OR) and 95% confidence intervals (CI) estimated from a logistic regression model with the following covariates: age, sex, African-American race,
hospitalization within 12 months prior to colonoscopy, hypertension, baseline GFR ≥60 and <90 mL/min, and current use of angiotensin-converting enzyme inhibitors, angiotensin-
renin blockers, thiazide, or loop diuretics;
‡Propensity score predicting the likelihood of use of polyethylene glycol or sodium phosphate, conditional on all covariates listed in Table 3 (age entered as a continuous variable),
as a covariate in a logistic regression model. Results when propensity score was used to stratify subjects into five approximately equal-sized strata, followed by Mantel-Haenszel
analysis were almost identical (OR 1.14, 95% CI 0.56–2.30).
Our study, therefore, aimed to clarify whether impaired
renal function after colonoscopy with oral sodium phos-
phates or PEG is an underrecognized problem in clinical
practice, and what risk factors may play a role. In addition,
we wanted to evaluate whether renal function is monitored
before and after colonoscopy, and whether the use of oral
sodium phosphates for bowel preparation complies with the
labeled restrictions in clinical practice, which can only be
addressed by an observational study in a clinical practice
setting.
Risk of Impaired Renal Function After Colonoscopy 2661
In the base population of all patients who underwent
colonoscopy and used sodium phosphate (Phospho-soda)
or PEG (COLYTE), we found a large number of patients
with preexisting renal disease, i.e., patients undergoing re-
nal dialysis, patients with a clinical diagnosis of acute or
chronic renal failure, and/or a GFR <60 mL/min. More than
half of all PEG users (56%) had such renal diseases within
12 months prior to colonoscopy. This high proportion is not
unexpected because use of sodium phosphate is not recom-
mended in patients with serious renal diseases, and PEG is a
possible alternative. Nevertheless, 15% of all patients using
sodium phosphate also had renal diseases within the pre-
ceding 12 months. In addition, the baseline renal function
was apparently not determined in 17.6% of sodium phos-
phate users; and in 22% of all users of sodium phosphate,
the last GFR before colonoscopy was <90 mL/min, but renal
function was apparently not monitored thereafter. Although
at least the higher use of PEG in 2005 is likely to be re-
lated to an increased awareness that sodium phosphate is not
recommended in patients with renal dysfunction, these re-
sults indicate a major discrepancy between its use in clinical
practice and the manufacturer’s recommendations regarding
restricted use and monitoring of renal function before and
after colonoscopy in patients at risk of renal dysfunction.
In the study population of patients without preexisting re-
nal dysfunction, the unadjusted as well as the adjusted RR
of renal impairment after colonoscopy were similar in users
of sodium phosphate as compared to PEG users. The simi-
larity between the unadjusted and the adjusted RR estimates
using two different methods supports the robustness of our
results regarding the assumptions of regression modeling and
indicates that the use of sodium phosphate is safe if labeled
contraindications and precautions are followed. The reason
for the restriction to patients without preexisting renal disease
and the focus on “idiopathic” renal impairment was that we
wanted to exclude patients in which the use of oral sodium
phosphate is not recommended. More importantly, particu-
larly in an observational study, it would have been virtually
impossible to differentiate whether a further decrease in re-
nal function after colonoscopy would be most likely related to
bowel preparation, or merely reflect a “natural” progression
of the preexisting renal disease. Further, differences in the
incidence of renal impairment between users of oral sodium
phosphate and PEG would have been confounded by the pref-
erential use of PEG in patients with preexisting renal disease,
and restriction is the most powerful and robust method to
control for confounding in this situation. We also excluded
patients without creatinine determination after colonoscopy,
because we would not have been able to evaluate the inci-
dence of subclinical chronic kidney injury in these patients.
Because we excluded patients without creatinine measure-
ments, we note that there may have been some selection
towards patients with a particular concern about renal im-
pairment in our study population. It is therefore likely that
the absolute risk of renal impairment was overestimated in
our study population as compared to the base population.
However, the necessary selection of patients with creatinine
determinations was applied to both PEG and sodium phos-
phate users, and therefore does not necessarily introduce bias
when comparing these two cohorts. At the same time, it is un-
likely that this exclusion would have prevented the detection
of clinically significant renal disease, because a clinical di-
agnosis would likely have been recorded and creatinine been
determined in such a situation.
The current study also identified risk factors of incident
moderate or severe renal dysfunction after colonoscopy. Pre-
existing mild renal impairment, high age, African-American
race, and hypertension were univariate predictors of renal im-
pairment after colonoscopy. Also, 42% of the patients with
renal impairment after colonoscopy had a recent prescription
for ACE inhibitors or angiotensin-renin blockers, as com-
pared to 23% in noncases. Similarly, in 21 reported cases
of renal failure after oral sodium phosphate use for bowel
preparation, eight (38%) had used these drugs (1, 3). Use
of thiazide diuretics was also associated with renal dysfunc-
tion in our study, and it is possible that drugs that affect fluid
and electrolyte balance including compensatory mechanisms
predispose to renal dysfunction after colonoscopy. Although
these univariate risk factors may in part be causally related to
each other, which prevents a reliable multivariate estimate of
their independent effects, they can serve as useful indicators
of an increased risk in clinical practice.
An important limitation of our study is the lack of a cre-
atinine determination soon after colonoscopy in all patients.
Transient decreases in GFR after colonoscopy may therefore
not have been captured in some patients. However, time from
colonoscopy to creatinine determination did not affect the RR
estimate when added to the regression model, and therefore
does not appear to be a significant source of bias in our study.
Further, as it is in the case for all observational research, the
possible effects of unknown or unmeasured confounders can-
not be addressed. On the other hand, the current study also
has important and unique strengths: (a) we present the first
population-based data evaluating the use and renal safety of
bowel preparation for colonoscopy in clinical practice, in-
cluding a large number of oral sodium phosphate users; (b)
all clinical information was continuously recorded, and diag-
noses were confirmed by review of original patient records,
which also confirmed the high quality of the HFHS patient
database in general; (c) as mentioned above, although PEG
is preferentially used in patients with preexisting renal dis-
ease, the exclusion of patients with preexisting severe renal
dysfunction led to a similar proportion of patients with preex-
isting mild renal dysfunction in our comparison groups, and
multivariate analysis with two different approaches provided
additional control for possible indication bias.
In summary, our results indicate that, in patients with no or
only mild preexisting renal dysfunction, the risk of moderate
or severe renal impairment after colonoscopy is not higher
after use of oral sodium phosphate versus PEG, and this in-
cludes an evaluation of subclinical functional renal damage
based on GFR estimates. The risk of severe irreversible re-
nal impairment after colonoscopy appears to be very low
in patients without preexisting renal disease. However, renal
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failure with a probable causal relationship to sodium phos-
phate has been well documented in a small number of patients
in the literature, most of which had risk factors that were also
found in our study. Therefore, our study does not argue with
the causation of impaired renal function in isolated cases,
and this may particularly affect patients with insufficient hy-
dration, diuretic treatment, and other risk factors. Indeed,
our results suggest that such risk factors may particularly
be an underrecognized problem in clinical practice, because
we found that many patients with preexisting renal disease
receive sodium phosphate without appropriate monitoring.
Future studies may further look at this particular population.
Therefore, it must be reemphasized that sodium phosphate
should not be used in patients with moderate or severe re-
nal impairment or in patients with congestive heart failure.
In the presence of risk factors of renal dysfunction, sodium
phosphate should be used cautiously, and this includes el-
derly patients and those taking drugs that affect fluid and
electrolyte balance such as ACE inhibitors, angiotensin-renin
blockers, and diuretics. Adequate hydration must be assured
in all patients using bowel preparation agents, and renal func-
tion should be monitored before and after colonoscopy in
those at risk of renal dysfunction.
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STUDY HIGHLIGHTS
What Is Current Knowledge
 Case reports of renal failure and nephrocalcinosis af-
ter use of oral sodium phosphates have raised safety
concerns.
 The labeling of oral sodium phosphates has been up-
dated and it recommends against using them in patients
at risk of renal dysfunction.
What Is New Here
 The risk of renal impairment after colonoscopy was
relatively low (<4%), and similar in users of sodium
phosphates and PEG with a glomerular filtration rate
(GFR) >60 mL/min.
 Contraindicated use of sodium phosphates by patients
with impaired renal function is not uncommon in clin-
ical practice.
 Renal function is frequently not determined before and
not monitored after colonoscopy, even in patients with
preexisting renal dysfunction.
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